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1. The sympathetic control of hypertension 
The autonomic nervous system includes afferent and efferent neurons connecting the 
central nervous system (CNS) and the visceral organs (Saper, 2002). The sympathetic and 
parasympathetic neurons represent the two major branches of the autonomic nervous system 
having the pivotal role to control organ functions and to maintain homeostasis by two serial 
neurons interconnected: the first is located in the CNS and the second in the peripheral 
ganglia. The parasympathetic neurons originate in the brain and in the sacral section of the 
spinal cord: ganglia are in or close to the innervated organs; the sympathetic neurons 
originate in the thoracic and lumbar sites of the spinal cord: ganglia are located in proximity 
of the spinal cord. 
This specific organization of the two systems allows to control physiological functions in 
peripheral districts in response to internal and external environmental stimuli (Saper, 2002). 
In the control of cardiovascular functions, the sympathetic nervous system (SNS) has been 
historically presented as opposing to the parasympathetic nervous system (PNS). The 
decrease in baroreceptor reflex activity and increase in chemoreceptor activity enhance the 
exaggerated sympathetic nerve activity (SNA) and reduce the parasympathetic nerve activity 
(PSNA) in cardiovascular diseases such as hypertension, atherosclerosis, myocardial 





Figure 1. Involved mechanisms in exaggerated sympathetic activity in 
cardiovascular disease and in hypertension.  





Moreover, several experimental evidences show to date a new aspect of the SNS as a key 
regulator of the cardiovascular system under physiological and pathological conditions. The 
sympathetic drive is implicated in the regulation of some functions in peripheral organs 
involved in the homeostasis of the cardiovascular system, such as the heart, vasculature and 
kidneys. A common feature of many cardiovascular diseases, like hypertension, is an 
increase of the SNA. In the past decades, the researches in this field invested many 
resources to develop experimental models of cardiovascular diseases and many techniques 
to analyze the dysregulation of SNS. The evaluation of the nervous trafficking in typical 
cardiovascular organs was a field of great interest allowing to important information on the 
mechanisms underlying the nerve reflexes involved in the regulation of blood pressure, in 
renal and cardiac function and in vascular contractility (Abboud, 1982; Guyenet, 2006; 
Malpas, 2010).  
Hypertension is a chronic elevation of blood pressure and although it is one of the most 
important human health problem (Lawes et al., 2008), the principal causes of the disease 
remain undefined. The etiology of hypertension cannot be often determined in the majority of 
patients with “essential” hypertension (Coffman, 2011) and the understanding of molecular 
mechanisms underlying the disease is crucial for basic and translational researchers in this 
field.  
Despite these advances, it has been difficult to treat hypertensive patients because the 
majority of these are unresponsive to ongoing treatment showing an increased SNA related 
to neural pathway in neurogenic hypertension (Mann et al., 2003). Furthermore, an increase 
of SNA is evident in the early stages of hypertension and it does not occur equally in all 
tissues, but a larger effect on occurs in key organs as the kidneys (Osborn et al., 2007). The 
sympathetic innervation of the kidney is considered the principal district in the regulation of 
blood pressure and the denervation of renal sympathetic fibers is a novel approach to treat 
uncontrolled hypertension (Esler, 2011; Coffman, 2011; Victor, 2015; see Figure 2). Decades 
of studies supported the efficacy of this approach and the neurogenic origin of hemodynamic 







Figure 2. Sympathetic neural mechanisms of blood pressure regulation 
and renal denervation. The scheme represents principal neural influences 
on sympathetic outflow to the heart, peripheral vasculature, and kidneys. 
Furthermore, three major components of the arterial baroreflex arc are 
shown: the afferent arm, the central integration and the efferent arm. 
By Victor, 2015. 
 
 
Although therapeutic strategies have been developed against the main components 
involved in blood pressure regulation, many patients are resistant to antihypertensive 
treatments, suggesting that there are still unidentified mechanisms underlying blood pressure 
control (Lawes, 2008). The Mosaic Theory of hypertension supports that many factors, 
including genetic, environmental, adaptive, neural and many others, can contribute to 
increase blood pressure (Page, 1967) highlighting that the disease is not predominantly 
caused by the perturbation of only one district as the renal one. Among these, some milestone 
papers suggest the role of inflammation in the development of hypertension (Guzik et al., 
2007; Vinh et al., 2010; Harrison, 2013). In this new point of view, the Theory by Dr. Page’s 
Mosaic (Page, 1967) represents a suggestion for further studies in the context of 




2. Neurogenic hypertension 
Hypertension is known as a neurogenic disease and the most probable cause is ascribable 
to an abnormality of the autonomic nervous system activity rather than a vascular or renal 
damage (Abboud et al., 2012; Victor, 2015). An alteration of neural control mechanisms 
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(vagal and sympathetic drive) of cardiovascular system is the principal feature of neurogenic 
hypertension (Zubcevic et al., 2011). As previously discussed, borderline hypertensive 
patients show an increased vasomotor and cardiac sympathetic drive and a reduction of 
parasympathetic one (Anderson et al., 1989; Grassi, 2009). Furthermore, hypertensive 
patients show a higher plasma norepinephrine level and norepinephrine spillover in both the 
peripheral circulation and blood draining from the brain and a raised sympathetic 
postganglionic activity in the skeletal muscle vascular bed (Anderson et al., 1989; Grassi, 
2009). In animal models of the disease, the mineralocorticoid excess, which depends on salt 
absorption from the kidney, have also been associated to an elevated sympathetic drive 
indicating a strong association between renal dysfunction and sympathetic overdrive (Krum 
et al., 2009). An evidence from spontaneously hypertensive rats demonstrates that the 
sympathetic over activity occurs before the onset of hypertension (Simms et al., 2009).  
The background level of the sympathetic tone is crucial for long-term blood pressure control 
and it is finely regulated by specific regions of central nervous system, as the rostral 
ventrolateral medulla (RVLM), the spinal cord, the hypothalamus and the nucleus of the 
solitary tract (NTS) (Guyenet, 2006; Victor, 2015). The renin-angiotensin system (RAS) is 
active in brain regions that regulate the sympathetic outflow and it is activated in different 
forms of hypertension. In particular, it is known that RAS maintains a state of sympathetic 
over activity acting on central neurons in the SFO (subfornical organ) (Coble et al., 2015) that 
is one of several circumventricular organs (CVOs) that lie outside the blood brain barrier 
(BBB) and thus have access to circulating AngiotensinII (AngII). A hypothesis by Osborn and 
colleagues on the neurogenic hypertension asserts that circulating AngII combined with high 
salt intake increases SNA in the disease (Osborn et al., 2007; see Figure 3). The brain 
targets for circulating AngII are neurons in the area postrema (AP), SFO and possibly other 
circumventricular organs. AngII signaling is integrated with sodium-sensitive neurons in the 
SFO and/or organum vasculosum of the lamina terminalis (OVLT) and drives sympathetic 
premotor neurons in the RVLM via the paraventricular nucleus (PVN) (Osborn et al., 2007). 
AngII has potent effects on blood pressure and cardiovascular function through its activation 
in these brain specific areas (Simpson, 1981) that are unprotected by the BBB coupling AngII 
signals with neural circuits that activated peripheral systems as the sympathetic drive 
involved in maintaining blood pressure homeostasis. The SFO is a region particularly 
populated by AngII receptors and more interestingly, studies have shown that the lesioning 
in this region markedly attenuated hypertension caused by an increase of circulating AngII 







Figure 3. Representation of the central hypothesis proposed by 
Osborn and colleagues. Central nervous system pathways involved in 
AngII–salt-dependent hypertension and schematic interface between neural 
pathways and cardiovascular target organs are shown. Furthermore, 
probable neural pathways from AngII and salt that influence neural control 
mechanisms of the cardiovascular system are illustrated. 
By Osborn et al, 2007. 
 
 
AngII is the principal molecule of the RAS raising blood pressure primarily through the 
activation of type 1 angiotensin (AT1) receptors (Crowley et al., 2004) and this signaling is 
well demonstrated by clinical trials showing the strong efficacy of AT1 receptor blockers 
(ARBs) in improving the complications of hypertension as well as the chronic kidney diseases 
(Lewis et al., 2001).  
The deoxycorticosterone acetate (DOCA)-salt provokes a different form of hypertension 
dependent on the altered regulation of central pressor mechanisms including the brain renin-
angiotensin system (Nishimura et al., 1999). AT1aR in the SFO, and possibly other nuclei, 
such as the PVN, contribute to the effects of DOCA-salt on arterial pressure and fluid and 
sodium intake, supporting the hypothesis that AT1aR signaling in the SFO is important for 
DOCA-salt hypertension (Grobe et al., 2011; Hilzendeger et al., 2013). In fact, the effect of 
SFO-targeted ablation of endogenous AT1aR is evaluated in AT1aRflox mice with deletion of 
AT1aR in SFO that exhibit a blunted increase in arterial pressure. Increased sympathetic 
cardiac modulation is significantly reduced in DOCA-salt mice when AT1aR is deleted in the 
SFO (Hilzendeger et al., 2013). These data highlight the contribution of AT1aR in the SFO to 
arterial blood pressure regulation by changes on sympathetic cardiac modulation in the 
DOCA-salt model of hypertension. It is known that chronic DOCA-salt treatment suppresses 
the peripheral RAS, but has different effects on the brain RAS as compared to chronic AngII. 
Chronic DOCA-salt causes a reduction in renal angiotensin converting enzyme (ACE) and 
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this treatment has no effect on the brain ACE (Nishimura et al., 1999). Conversely, 
Angiotensinogen is down regulated by DOCA-salt treatment in both kidney and brain 
(Nishimura et al., 1999). The majory of studies have indicated that DOCA-salt hypertension 
is principally mediated by the activation of the brain RAS (Schenk and McNeill, 1992). In fact, 
DOCA-salt treatment results in increased angiotensin receptor density specifically in 
cardiovascular control regions of the brain, including the subfornical organ, median preoptic 
nucleus, paraventricular nucleus, and area postrema (Palkovits and Záborszky, 1977; 
Mangiapane and Simpson, 1980; Gutkind et al., 1988; Nishimura et al., 1999).  
More interestingly, neurons from these same forebrain regions extend to sites critical to the 
emotional stress response, including the bed nucleus of the stria terminalis (Sunn et al., 
2003). Psychological stress can contribute to the development of hypertension and has been 
correlated with an excessive rise in blood pressure in patients with unstable hypertension 
(Matthews et al., 2004).  In animal model, a repeated exposure or chronic stress elicits 
changes in baseline blood pressure (Alkadh et al., 2005). It has been observed that emotional 
stress can also activate the RAS and thus increase endogenous production of AngII (Krause 
et al., 2011). Indeed, a study conducted by Harrison group demonstrates that the AngII 
infusion increases blood pressure reactivity to acute stress, vascular inflammation and 
corticotrophin releasing hormone (CRH) gene expression in the PVN, showing for the first 
time that psychological stress enhanced both the central neurohormonal stress response and 





3. The role of the immune system in hypertension 
Simultaneously with the recognition that CNS and SNS play a crucial role in hypertension, 
it has been recognized that chronic functional and structural alterations observed in 
hypertension are determined by the inflammatory system that causes damage in target 







Figure 4. Sympathetic and immune system interplay in cardiovascular 
disease. The triangle reflects the convergence of the neural and immune 
mechanisms in cardiovascular disease.  
By Abboud et al., 2012. 
 
 
Immune organs are densely innervated by the SNS and in particular, the spleen is a 
reservoir of immune cells of both the innate and the adaptive immune systems (Lori et al., 
2017; Nance and Sanders, 2007). Many evidence suggest that the immune system 
contributes to the development of the hypertension (Guzik et al., 2007; Wenzel et al., 2011). 
An old study demonstrated that mice with genetic aplasia of the thymus are protected from 
the onset of the disease, suggesting that the adaptive immunity could have a key role in the 
hypertension (Svendsen, 1976). Additionally, the transfer of splenic cells from hypertensive 
rats promoted an elevation of blood pressure in control recipient rats (Olsen, 1980). After, the 
idea is corroborate by experiments in which it was found that the immunosuppression 
attenuated hypertension in Okamoto spontaneously hypertensive rats and reduced the renal 
damage in Sprague-Dawley rats (Khraibi et al., 1984). Moreover, the most significant studies 
highlighting the importance of immune cells in hypertension came from the David Harrison 
laboratory. They showed that immune cells are crucial players in hypertension in mice 
chronically treated with AngII and that mice deprived of lymphocytes are protected from 
AngII-induced hypertension (Guzik et al., 2007). Additionally, by the same group, it was found 
that CD8 KO mice, but not CD4 KO mice, are protected from hypertension, leading to a further 
knowledge of the immune mechanisms involved in the onset of the disease (Vinh et al., 
2010). In particular, chronic AngII causes an increase of cells expressing CD86 in the splenic 
marginal zone. The CD86 is a marker of co-stimulation, a pathway elicited by antigen 
presenting cells (APCs). This research demonstrated a dealing between innate and adaptive 
immunity during the development of hypertensive disease (Vinh et al., 2010). These 
investigators also showed that T cells were essential for other forms of hypertension, as 
induced by DOCA-salt and norepinephrine (Guzik et al., 2007; Marvar et al., 2010), 
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suggesting that the inflammatory component participates to a mechanism crucial for the 
development of the disease. 
Another work, more important in this field, has been described by Wenzel and colleagues 
that  reported that mice with deletion of Lysozyme M (LysM) positive macrophages, obtained 
by a selective deletion of monocyte/macrophages, were protected from vascular dysfunction 
and hypertension in murine model of AngII (Wenzel et al., 2011). Furthermore, Crowley and 
colleagues showed that immune system is essential for developing of hypertension and mice 
with immune deficiency are protected from the blood pressure increase (Zhang and Crowley, 
2015). This group found that mice unable to support a Th1 response due to deficiency of the 
transcription factor, T-bet, had preserved hypertensive responses but were protected from 
renal damage during chronic AngII administration, suggesting that Th1 cells increase the 
damage of hypertensive target organs as kidney through mechanisms independents from 
blood pressure regulation (Zhang et al., 2012). T cells are involved in the development of 
other forms of hypertension as Dahl-sensitive rats in which are crucial for the increase of 
blood pressure levels (De Miguel et al., 2010; Mattson, 2014). 
More recently, Tracey and colleagues showed that mice lacking ChAT expression in CD4+ 
T cells have an elevation of arterial blood pressure levels as compared to control mice and 
conversely, Jurkat T cells overexpressing ChAT (JTChAT) decreased blood pressure when 




3.1 Inflammatory “Priming” in hypertension 
Macrophages and neutrophils of the innate immunity are the first line of defense against 
pathogens, while lymphocytes of the adaptive immunity provide increased protection against 
reinfection by the same pathogen. Conversely, to innate immunity, the adaptive immune 
system is highly specific. In the adaptive immunity, the APCs capture and process proteins 
of pathogen into small peptides that then are presented as major histocompatibility complex 
(MHC). T lymphocytes activation is mediated by dendritic cells (DC) that process antigens 
and present the peptides within MHC II. Dendritic cells then migrate to secondary lymphoid 
organs, including the spleen and lymph nodes, where they activate a T cell with a T cell 
receptor able to recognize the antigenic peptide. This interaction is termed “immunologic 
synapse.” An important interaction in this site is the costimulation that involves B7 ligands on 
the APCs (CD80 and CD86) with CD28 on the T cell (Harrison et al., 2011). After the 
costimulation, T cells start to proliferate and produce cytokines altering the expression of 
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receptors that lead to their egression from the secondary lymphoid organs towards sites of 






Figure 5. Priming of the immune response. In the classical immune 
response, foreign proteins are processed in dendritic cell and are presented 
on surface within an MHC. In hypertension, it is hypothesized that 
endogenous proteins are modified, by oxidation, fragmentation, or other 
modifications and they are not recognized as self. T cells are activated by 
costimulation pathway and egress from secondary lymphoid organs towards 
target organs of inflammation, typical of hypertensive disease, as kidney and 
vessels. 
By Harrison et al., 2011. 
 
 
Activated T cells enter the kidney and vasculature where the cytokine IL-17 promotes the 
entry of other inflammatory cells such as macrophages. These inflammatory cells release 
cytokines that cause vasoconstriction promoting sodium and water absorption and causing 
hypertension. IL-17 is implicated in a variety of diseases including rheumatoid arthritis 
(Witowski et al., 2004). It is produced by TH17 cells, a subset of CD4+ cells (Witowski et al., 
2004), and also by CD8+ cells (Kondo et al., 2009). Very interesting, the increase of blood 
pressure levels in mice lacking IL-17 was comparable to that observed in wild-type mice, 
resulting protected from hypertension. It was demonstrated that IL-17 promoted the 
chemotaxis of other inflammatory cells, stimulating the release of other chemokines 
(Hartupee et al., 2007). Indeed, the vascular accumulation of leukocytes (including T cells) 
caused by angiotensin II is reduced in IL-17-/- mice, contributing to the vascular 
pathophysiology of hypertension, demonstrating the importance of the adaptive immune 
response in the onset of hypertensive disease.  
A very old work showing the role of the central nervous system in peripheral vascular 
inflammation demonstrated that lesions in the anteroventral 3rd ventricular (AV3V) prevented 
hypertension and the activation of circulating T cells and the infiltration of leukocytes caused 
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by AngII. This finding showed that the direct actions of AngII on T cells and peripheral tissues 
are not responsible for the inflammation but that it was required a central action of AngII to 
establish the inflammation in AngII-induced hypertension (Brody et al., 1978).  
Several studies have linked the central nervous system to inflammation. The sympathetic 
fibers terminate in definite areas of the spleen reached of T cell (Lori et al., 2017) where they 
release norepinephrine as the principal neurotransmitter, which can both inhibit and stimulate 
T cell activation and proliferation (Madden et al., 1995). Norepinephrine stimulates naïve CD4 
lymphocytes cultured under TH1-promoting conditions to produce more IFN than in non-
stimulated cells (Swanson et al., 2001). Very intriguingly, Ganta and colleagues 
demonstrated that intracerebroventricular administration of AngII increased splenic 
sympathetic nerve activity (SSNA), which in turn stimulated mRNA expression of several 
cytokines in splenocytes. Splenic sympathectomy abrogated these effects suggesting a clear 
link between the central action of AngII and the immune responses in the spleen (Ganta et 





Figure 6. Central AngII increases splenic nerve discharge and activates 
immune system. The sympathetic innervation of the spleen provides a 
direct link between central sympathetic neural circuits and 
immunocompetent cells in the spleen. 
By Ganta et al., 2005. 
 
 
The sympathetic innervation of the spleen provides a direct link between central 
sympathetic neural circuits and immune responses in this lymphoid organ (Felten, 1985; 
Felten and Olschowka, 1987), and changes in the level of efferent splenic sympathetic nerve 
discharge (SND) can alter immune responses in the spleen (Ganta et al., 2005). These data 
introduce the concept of the anti-inflammatory neural reflex in hypertensive disease in which 





4. The neural-inflammatory reflex  
The inflammatory reflex describes that the CNS responds to inflammatory stimuli acting to 
limit peripheral or systemic inflammation (Tracey, 2002; Rosas-Ballina and Tracey, 2009; 
Rosas-Ballina et al., 2011). Considerable works demonstrate that the ‘cholinergic anti-
inflammatory pathway’ constitutes the efferent neural arm of the inflammatory reflex (Huston 
et al., 2009; Rosas-Ballina et al., 2011). Tracey and colleagues have focused on the role of 
vagus nerve dependent circuits to control innate immunity (Borovikova et al., 2000; Huston 
et al., 2009; Pavlov et al., 2009; Rosas-Ballina et al., 2011; Reardon et al., 2013). The vagus 
nerve is the mediator of both the afferent and efferent signals of the neural reflex (Rosas-
Ballina and Tracey, 2009; see Figure 7). Vagal afferents are widely distributed in most 
visceral organs and it can be activated by the release of cytokines from tissue injury or 
inflammation (Rosas-Ballina and Tracey, 2009; see Figure 7). The reflex is then centrally 
mediated through the NTS and the dorsal motor nucleus of the vagus and activates the vagal 
efferent. When activated, the vagal efferent suppresses the cytokine release from 
macrophages in the spleen. The circuit requires acetylcholine (ACh) signaling through α7 
nicotinic receptors (see Figure 7) (Rosas-Ballina et al., 2011; Reardon et al., 2013). Memory 
T-lymphocytes are components of the peripheral neural control of innate immunity in the 




Figure 7. The Inflammatory Reflex. Control systems orchestrated by the 
autonomic nervous system integrate input signals and deliver responses. 
Cytokines produced by immune cells in response to endogenous and 
exogenous stimuli activate afferent neurons of the vagus nerve that conveys 
this information to the brain where signal integration occurs. A response is 
elicited through the cholinergic anti-inflammatory pathway, the efferent arc 
of this inflammatory reflex, which modifies immune function and maintains 
homeostasis.  
By Rosas- Ballina and Tracey, 2009. 
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Borovikova and colleagues found that cutting the vagus nerve in anaesthetized rats caused 
a 40% increase in their inflammatory response (measured by TNF plasma levels) to a high 
dose of intravenous lipopolysaccharide (LPS) (Borovikova et al., 2000). Conversely, Martelli 
and colleagues measured plasma TNF responses to intravenous LPS in anaesthetized rats 
finding that cutting the vagus nerve had no effect on this measure of inflammation (Martelli et 
al., 2014). Moreover, sectioning of the splanchnic sympathetic nerves increased the TNF 
response to LPS five-fold, concluding that the efferent arm of the inflammatory reflex is 
mediated by the splanchnic sympathetic nerves but not by the vagus nerve (Martelli et al., 




4.1 7nAChR in the inflammatory reflex 
Substantial literature from Tracey research group confirms that the cholinergic anti-
inflammatory pathway conveys signals from the brain to the spleen via the vagus nerve and 
the splenic nerve and it is dependent on the 7 subunit of the nicotinic acetylcholine receptor. 
In fact, activation of cholinergic anti-inflammatory pathway by electrical stimulation of the 
vagus nerve (VNS) or administration of 7 selective drugs is effective in ameliorating 
inflammation and improving survival in experimental models of sepsis (Borovikova et al., 
2000). 
7 is the subunity of nicotinic acetylcholine receptor. Nicotinic receptors nAChRs are ligand-
gated ion channels comprising a family of hetero- or homopentameric structures derived from 
the products of 17 genes. They are excitatory receptors for the neurotransmitter acetylcholine 
playing a crucial role in the central and peripheral nervous system (Chatzidaki and Millar, 
2015). In brain neurons, 7 is a homo pentameric calcium channel expressed predominantly 
in presynaptic nerve terminals where it modulates neurotransmitter release and in 
postsynaptic neurons where it induces excitatory signals. Sixteen human nAChR subunits 
(1-7, 9, 10, 1-4, ,  and ) have been identified. The 7 subunit is more widely 
referred as neuronal subunit (Millar and Gotti, 2009) and it forms functional homomeric [(7)5] 
nAChRs. It is considered atypical and it has a relatively low sensitivity to acetylcholine, high 
calcium permeability and exhibits very fast desensitization (Couturier et al., 1990). Each 
nAChR subunit contains an amino-terminal extracellular domain and four transmembrane 
helices (TM1-TM4). The pore of the channel is lined by the second transmembrane domain 
(TM2) from five co-assembled subunits (Millar and Gotti, 2009; see Figure 8). 
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In the central nervous system, 7 is associated with neuronal plasticity (Berg and Conroy, 
2002). In macrophages, signaling through 7 attenuates TNF production through a 
mechanism dependent upon inhibition of NF-κB nuclear translocation and activation of Jak-
STAT pathways (Borovikova et al., 2000). Furthermore, these receptors are expressed in 





Figure 8. Cartoon representation of nAChR structure and subunit 
topology.  
By Chatzidaki and Millar, 2015. 
 
 
Interestingly, 7nAChR actively participates to the cholinergic anti-inflammatory reflex and, 
though initially discovered as a modulator of macrophage function, has been shown to couple 
the vagus-splenic connection at the neuronal level (Rosas-Ballina et al., 2008; Vida et al., 
2011). Yet 7nAChR is not required for the parasympathetic modulations exerted by the 
vagus nerve in typical cardiovascular parameters such as heart rate (Deck et al., 2005).  
The spleen contains acetylcholine and a direct electrical stimulation of the splenic nerve 
mediates the release of acetylcholine in the lymphoid organ (Leaders and Dayrit, 1965). 
Since the spleen lacks cholinergic nerve fibers (Bellinger et al., 1993), acetylcholine in this 
lymphoid organ may be derived from lymphocytes and other immune cells that synthesize 
and release acetylcholine close to nerve endings (Kawashima and Fujii, 2004). This may 
explain how electrical stimulation of the vagus nerve can induce acetylcholine release in the 
spleen, which in turn regulates cytokine release through 7 expressed on responding cells 
(Rosas-Ballina et al., 2008). Vida and colleagues show that vagus nerve modulates systemic 
norepinephrine via the splenic nervethrought7nAChR and the spleen and furthermore that 
the vagotomy prevents afferent vagus nerve towards the central nervous system. Both vagus 
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nerve stimulation and 7nAChR agonists in mice activate the splenic nerve to produce 
norepinephrine via the 7nAChR. These results demonstrates that acetylcholine released by 
the vagus nerve in the celiac mesenteric ganglia is able to activate postsynaptic 7nAChR 
of the splenic nerve, leading to the release of norepinephrine in the spleen. The anti-
inflammatory potential of the vagus nerve and 7nAChR agonists is inhibited by splenectomy 
or splenic neurectomy. Splenic nerve stimulation, performed via an abdominal flank incision, 
mimics the anti-inflammatory mechanism of the vagus nerve and 7nAChR agonists to 
induce norepinephrine and to prevent LPS-induced serum TNF levels (Vida et al., 2011; see 
Figure 9). More interestingly, the vagus nerve stimulation is recently shown to mediate 
protection from kidney ischemia-reperfusion injury through 7nAChR in splenocytes (Inoue 
et al., 2016). 
 
 
Figure 9. 7nAChR represents a unique molecular link between the 
parasympathetic and sympathetic system to control inflammation. 
Splenic nerve stimulation (SNS) mimics vagal and cholinergic induction of 
norepinephrine (NE) and re-establishes neuromodulation in 7 nicotinic 
acetylcholine receptor (7nAChR)-deficient mice. Vagus nerve and 
cholinergic agonists inhibit systemic inflammation by activating the 
noradrenergic splenic nerve via the 7nAChR nicotinic receptors. 





5. The involvement of the splenic PlGF in hypertension 
The Placental growth factor (PlGF) is a member of the vascular endothelial growth factor 
(VEGF) family. Besides to PlGF, VEGF family includes VEGF-A, -B, -C, and –D. These 
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growth factors were identified as promoters of proliferation, migration and survival of 
endothelial cells (Leung et al., 1989) and they have been implicated in inflammatory 
processes, including rheumatoid arthritis, cancer and inflammatory bowel disease (Kuenen 
et al., 2002). In fact, increased levels of VEGF in animal and human models of sepsis (Yano 
et al., 2006; Yano et al., 2008) and the inhibition of their signaling with soluble fms-like 
tyrosine kinase-1 (sFlt-1) or antibodies against flt-related receptor tyrosine kinase-a (Flk-1) 
improved morbidity and mortality in sepsi (Yano et al., 2006). Furthermore, circulating levels 
of PlGF are normally undetectable but an increase of PlGF levels have been described in 
several conditions, including cancer (Chen et al., 2004) and sepsi (Yano et al., 2008). 
Originally, PlGF was identified in the placenta (Khaliq et al., 1996) but it has subsequently 
been shown to be expressed in other tissues, including the heart, lung, thyroid gland and 
skeletal muscle (Autiero et al., 2003). PlGF is also found to be expressed in cardiac tissue. 
In this tissue, PlGF increases in hypoxic/ischemic myocardium (Torry et al., 2009), 
contributes to pathological angiogenesis (Carmeliet et al., 2001; Lutton et al., 2002) and 
atherosclerosis (Khurana et al., 2005) and may have both positive and negative effects on 
tumor growth (Fischer et al., 2007; Van de Veire et al., 2010). These aspects show how the 
environment can influence its effects. 
Furthermore, it was found that PlGF acts as a chemotactic agent for monocytes (Pipp et al., 
2003) that participate in the cardiac inflammatory response to pressure overload and support 
adaptive cardiac remodeling (Endo et al., 2007). PlGF is considered a regulator of the tissue 
inhibitor of metalloproteinases-3/tumor necrosis factor--converting enzyme axis and the 
consequent TNF- activation in response to transverse aortic constriction, thus allowing the 
establishment of an inflammatory response necessary for adaptive cardiac remodeling 
(Carnevale et al., 2011). 
A consistent and increasing amount of reports associates the use of anti-angiogenic 
therapies based on inhibitors of the VEGF, with an increase of cardiovascular risk and in 
particular, the development of hypertensive disease (Small et al., 2014). There are important 
papers reporting the protective effects of PlGF inhibition in various models of cancers, where 
the main results were obtained in terms of inhibition of tumor growth through immuno-
modulating functions (Snuderl et al., 2013). Indeed, the inhibition of PlGF in cancer seems to 
have a dual positive role: on the one hand, it would protect from tumor growth (Van de Veire 
et al., 2010; Snuderl et al., 2013; Incio et al., 2016) and at same time hamper hypertension 
(Carnevale et al., 2014).  
Carnevale and colleagues demonstrated that PlGF inhibition was associated with a 
protection from blood pressure increase and target organ damage in the experimental model 
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of hypertension induced by chronic infusion of AngII (Carnevale et al., 2014). To define 
unambiguously the role of PlGF in the onset of hypertension through modulation of the 
immune system in the splenic reservoir, Carnevale and colleagues studied chimeric mice, 
generated by spleen transplantation among WT mice and PlGF-deficient mice. Chimeric mice 
were then subjected to chronic AngII infusion. In WT mice that received PlGF-deficient 
spleens, AngII failed to raise blood pressure and to mobilize T cells towards target organs of 
hypertension as aorta and kidney (Carnevale et al., 2014; see Figure 10). With these 








Figure 10. Splenic PlGF in hypertension. Blood pressure (BP) 
responses to chronic AngII, in different groups of chimeric mice, 
obtained by spleen transplantation among PlGF-deficient (PlGF KO) 
mice and WT mice. In this figure, it is represented a cartoon with chimeric 
mice obtained after spleen transplantation (up and left panel); the 
accumulation of T cells from the donor spleen (CD45.1) measured by flow 
cytometry (up and right panel);   BP response to chronic AngII, in 
splenectomized WT versus sham mice (down and left panel); BP response 
to chronic AngII, in different groups of chimeric mice, obtained by spleen 
transplantation among PlGF-deficient (PlGF KO) mice and WT mice. 
By Carnevale et al. 2014.  
 
 
Furthermore, Carnevale and colleagues also identified an epigenetic modulation in which 
PlGF was able to mediate the mechanism of T cells costimulation (Carnevale et al., 2014). 
PlGF is expressed in the marginal zone of the spleen, in a network of fibroblastic reticular 
cells (FRCs), identified by ER-TR7 and CD169 antigens. In this zone, the spleen is 
particularly enriched of macrophages and DCs, acting as APCs, and directly or indirectly 
activating T cells. In the Harrison lab, it has been demonstrated that the AngII hypertensive 
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challenge is able to increase the percentage of the co-stimulatory molecule CD86 (Vinh et 
al., 2010). Carnevale and colleagues found that after AngII, the absence of PlGF significantly 
protected from CD86 increase in the marginal zone of the spleen, promoting PlGF as a crucial 
regulator of neuroimmune dealing in hypertensive condition (Carnevale et al., 2014; 
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Abstract 
The crucial role of the immune system in hypertension is now widely recognized. We 
previously reported that hypertensive challenges couple the nervous drive with immune 
system activation, but the physiological and molecular mechanisms of this connection are 
unknown. Here, we show that hypertensive challenges activate splenic sympathetic nerve 
discharge to prime immune response. More specifically, a vagus-splenic nerve drive, 
mediated by nicotinic cholinergic receptors, links the brain and spleen. The sympathetic 
discharge induced by hypertensive stimuli was absent in both coeliac vagotomized mice and 
in mice lacking 7nAChR, a receptor typically expressed by peripheral ganglionic neurons. 
This cholinergic-sympathetic pathway is necessary for T cell activation and egression on 
hypertensive challenges. In addition, we show that selectively thermoablating the splenic 
nerve prevents T cell egression and protects against hypertension. This novel experimental 




Despite the wide spectrum of antihypertensive medications currently available, a significant 
proportion of patients still have poorly controlled blood pressure and, consequently, resistant 
hypertension1,2,3. In the first half of the past century, the Mosaic Theory of Hypertension 
proposed that many factors, including genetics and environment as well as nervous, 
mechanical and hormonal perturbations, interplay to raise blood pressure4. Because the 
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aetiology of hypertension is multifaceted, its solution must involve more than a single 
anatomical organ. 
In the last decade, immunity emerged as a crucial player in hypertension: immune cells 
infiltrate the vessel walls and kidneys of hypertensive animals, and mice without lymphocytes 
are protected from angiotensinII (AngII)-induced hypertension5,6,7,8,9. Despite growing 
awareness of immune cells’ role in hypertension, blood pressure control has been considered 
primarily the work of the autonomic nervous system10. The sympathetic nervous system, by 
contrast, has historically been thought to influence blood pressure control via regulation of 
key physiological parameters including heart rate, vascular tone and renal sodium excretion3. 
Clinically, sympathetic innervation of the kidney has been seen as the cause of hypertension, 
and renal denervation has been regarded as an intriguing new approach to treating 
uncontrolled high blood pressure11,12,13. 
The autonomic nervous system also regulates of immunity14,15,16,17, though its role is often 
overlooked. Previously, we have found that placental growth factor (PlGF), an angiogenic 
growth factor belonging to the vascular endothelial growth factor (VEGF) family, links the 
nervous drive to immune system activation7. We performed a coeliac ganglionectomy to 
selectively disrupt sympathetic innervation of splanchnic circulation and found that PlGF 
activation, immune system recruitment and increased blood pressure depend on this 
pathway7. Interestingly, preliminary studies indicated that splanchnic innervation would 
impact hypertension18. However, two main questions remain unanswered: (i) which 
splanchnic nervous compartment is responsible for these effects on immunity and blood 
pressure regulation and (ii) how is the brain-to-splanchnic compartment connection 
established at the onset of hypertension. 
 
Hypertensive stimuli activate splenic nerve discharge 
Although chronic AngII has been shown to be a potent driver of splanchnic circulation18, we 
do not yet know which downstream nervous district is engaged by hypertensive stimuli to 
increase blood pressure. The chronic effects of AngII are mediated by brain signals 
transmitted via the peripheral networks19. Indeed, lesions in central nervous system organs, 
which are able to sense peripheral challenges, prevent AngII infusion from raising blood 
pressure19. Taken together, these connections suggest that peripherally-delivered 
hypertensive stimuli activate a nervous drive in the brain that is conveyed through splanchnic 
circulation. Given that immune system activation in hypertension depends on the same 
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pathway, we hypothesized that the splenic nerve could be the splanchnic innervation 
connecting the brain and immune cells. 
To test this idea, we established a procedure for recording sympathetic nerve activity (SNA) 
in mice. First, we validated splenic nerve SNA (SSNA) recording by inducing reflex responses 
to blood pressure changes. We pharmacologically manipulated blood pressure with sodium 
nitroprusside and phenylephrine to evaluate typical SNA reflex responses (Supplementary 
Figs 1 and 2). We found that SSNA increased quickly in response to lowered blood pressure, 
as expected for sympathetic activity (Supplementary Fig. 1a–c). To further assess nerve 
activity, we evaluated synchronous sympathetic bursts. Analysis of SSNA showed that most 
nerve bursts synchronized with raw blood pressure signal (Supplementary Fig. 1d,e), a result 
that is consistent with the semirhythmic SNA observed in nerves in nearby compartments, 
including the splanchnic10,20,21,22. Ganglionic blockade with hexamethonium abolished SSNA 
activity (Supplementary Fig. 1f), which overlapped the residual postmortem recording 
(Supplementary Fig. 1g) that was used thereafter as the positive action potential threshold. 
As expected, the opposite response was observed when mice were challenged with 
phenylephrine to acutely increase blood pressure. Indeed, the SSNA, although similarly pulse 











After validating the direct SSNA recording method, we tested whether chronic AngII infusion 
activates SSNA to modulate subsequent T cell activation. To avoid the potentially 
confounding effects of increased blood pressure itself, we analyzed mice 3 days after starting 
AngII infusion, when blood pressure has not yet significantly changed (Supplementary Fig. 
3). To find the appropriate time point for examining the connection between nervous drive 
and immune activation, we performed a time course analysis of T cell recruitment in target 
organs. After 3 days, we could detect T cells in the aortas (Supplementary Fig. 4a,b) and 









Next, we used a bipolar electrode to record SSNA in splenic nerve bundles in mice infused 
with either AngII or Vehicle (Fig. 1). A representative recording of splenic nerve discharge 
clearly shows increased rhythmic SSNA bursts above the background noise, as defined by 
the postmortem recording (Fig. 1a,b). Simultaneous blood pressure recording demonstrated 
animal stability during the procedure (Fig. 1c). Changes in SSNA included increases in either 
the number of sympathetic bursts or the amplitude of individual bursts. We found that AngII-
infused mice had significantly higher SSNA, measured both as firing frequency (Fig. 1d) and 





Figure 1. AngII activates discharge of the splenic nerve. a,b) Representative 
raw signals of SSNA in a time bin of 10 min in (a) show a significantly increased 
nerve discharge in AngII-infused mice as compared with vehicle. Raw signal of 
residual SSNA during postmortem was used to identify the signal threshold level 
for each recording. In (b) it is represented an enlarged view of 10 s of SSNA raw 
signal from the red window in a. (c) Blood pressure (BP) monitoring during SSNA 
recording excluded hemodynamic effects. (d) Firing frequency, represented by the 
mean number of spikes in a time bin, was significantly higher in AngII-infused mice 
as compared with vehicle (vehicle nmice=8 and AngII nmice=10; independent samples 
Student’s t-test, t(16)=−4.697, ***P<0.001). (e) Analysis of mean amplitude gain of 
spikes showed that AngII-infused mice had also increased SSNA in the pattern of 
burst amplitude as compared with vehicle (vehicle nmice=8 and AngII nmice=10; 
independent samples Student’s t-test, t(9)=−3.120, **P<0.01). 
 
To determine if the increased SSNA was a selective response to AngII, we also performed 
experiments with deoxycorticosterone acetate (DOCA)-salt hypertensive mice, a model 
characterized by increased AngII levels in the brain and reduced peripheral renin–
angiotensin system (RAS) activation23. As in the experiments detailed above, in this model 
we studied mice at the beginning of blood pressure increase (Supplementary Fig. 5) and 
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again found elevated SSNA (Fig. 2a–c). Quantitative analysis confirmed that SSNA activation 
is similar in DOCA-salt-treated mice and AngII-hypertensive mice (Fig. 2d,e), thereby 
suggesting the brain-to-splenic nerve drive is a common pathway for hypertensive challenges 








Figure 2. Activation of splenic nerve activity is a common response to 
hypertensive stimuli. a–c) DOCA-salt hypertensive challenge significantly 
increased splenic nerve discharge, in a similar way to that observed in AngII-infused 
mice, as shown by the representative raw signals of SSNA in a time bin of 10 min 
(a) and a particular of 10 s from the red window in b. Residual SSNA during 
postmortem (lower panel in a) and BP monitoring (c) are shown as well. (d) DOCA-
salt induced a significant increase in firing frequency, expressed as the mean 
number of spikes in a time bin, as compared with mice receiving placebo (Placebo 
nmice=6 and DOCA-salt nmice=7; independent samples Student’s t-test, t(11)=−9.654, 
***P<0.001). (e) DOCA-salt-treated mice display a significant higher mean amplitude 
gain of spikes, as compared with mice receiving placebo alone (Placebo nmice=6 and 
DOCA-salt nmice=7; independent samples Student’s t-test, t(11)=−5.977, 
***P<0.001). 
 
The vagal-coeliac-splenic connection mediates hypertension 
Sympathetic innervation of the spleen has been recognized as a crucial mechanism for 
modulating immune cell functions24,25,26. For many years, autonomic innervation of immune 
organs did not seem relevant to cardiology, but current evidence for immunity’s vital role in 
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blood pressure regulation necessitates investigating neuro-immune reflexes in hypertension. 
Sympathetic and parasympathetic innervations of the splanchnic organs have been 
traditionally regarded as anatomically separate along their peripheral routes. If the 
innervations are indeed separate, the splenic nerve should be activated by a pre-ganglionic 
neuron in the paravertebral ganglia chain that connects to the intermediolateral grey column 
in the spinal cord. However, immunologists have identified a cholinergic anti-inflammatory 
reflex that is mediated by the vagus nerve’s coeliac branch and specifically targets splenic 
innervation during septic challenges24,25,26,27. 
To investigate whether and how vagal signals could affect splenic nerve activity during 
hypertensive challenges, we performed cervical vagotomy while recording SSNA (Fig. 3a–
c). Cervical vagotomy completely prevented AngII from activating the splenic nerve (Fig. 
3a,b). These results indicate that AngII-induced splenic nerve activation is mediated by the 
cervical vagus nerve. Unexpectedly, we found no reduction in residual SSNA gain amplitude 
after both cervical and coeliac vagotomy (Fig. 3c), a result that suggests hypertensive stimuli 
use different sympathetic pathways for SSNA firing frequency and individual burst amplitude. 
As previously reported concerning the regulation of other organs10, our results indicate that 
a specific brain cell network produces rhythmical discharges in the splenic nerve through the 
vagus connection. Conversely, other central nervous system cell groups regulate splenic 
nerve gain amplitude independently from the vagus nerve. To further uncover the relative 
contributions of the vagus nerve’s afferent versus efferent arms, we performed a coeliac 
vagotomy that also completely inhibited AngII-induced SSNA (Fig. 3d,e), still with no effect 
on the gain amplitude of splenic nerve activity (Fig. 3f). In addition, we analyzed the chronic 
response to AngII in mice with left coeliac vagotomy. Inhibiting vagus nerve efferents 
hampered the blood pressure increase typically induced by AngII (Fig. 4a,b) as well as the T 






Figure 3. Efferent vagus nerve resection blocks the SSNA induced by 
hypertensive stimuli. (a) Mice infused with AngII were subjected to cervical 
vagotomy (VagX) while recording SSNA. As shown by the representative raw signals 
of SSNA, cervical VagX completely abolishes splenic nerve activity. (b) Analysis of 
firing frequency confirmed the inhibitory effect of cervical VagX on AngII-induced 
SSNA (nmice=5; paired samples Student’s t-test, t(4)=8.524, ***P<0.001). (c) 
Conversely, no effect of cervical VagX on the mean amplitude gain of spikes was 
observed, suggesting that this pattern of SSNA was regulated by pathways different 
from the vagus nerve (nmice=5; paired samples Student’s t-test, t(4)=−2.764, 
P=0.051). (d) To verify whether the effect was due to the afferent or efferent branch 
of the vagus nerve, a further group of AngII-infused mice underwent coeliac 
vagotomy (VagX) while recording SSNA. Even in this case, splenic nerve activity 
was completely inhibited by coeliac VagX. (e) Analysis of firing frequency confirmed 
the inhibitory effect of coeliac VagX on AngII-induced SSNA (nmice=5; paired samples 
Student’s t-test, t(4)=11.059, ***P<0.001). (f) Yet, no effect of coeliac VagX on the 
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mean amplitude gain of spikes was observed, further supporting that this pattern of 
SSNA was regulated by pathways different from the vagus nerve (nmice=5; paired 





Figure 4. Coeliac vagotomy protects from AngII-induced blood pressure 
increase and T cell egression. a,b) Mice with left coeliac VagX did not become 
hypertensive in response to chronic AngII infusion (nmice=5 for each group; two-way 
ANOVA for repeated measures; (a) systolic blood pressure SBP, 
F(interaction)=3.321, ***P<0.001; (b) Diastolic blood pressure DBP, 
F(interaction)=2.284, ***P<0.001). (c) Left coeliac VagX was also effective in 
inhibiting the T cell egression induced by AngII, as evidenced by the area of CD3+ 
cells (magenta), representing the white pulp and delimited by B220+ cells (green) 
delineating the red pulp (scale bar, 200 μm). (d) Graph showing the relative 
quantitative analysis (nmice=5 for each group; two-way ANOVA, 
F(interaction)=20.160, **P<0.01). 
 
Overall, these results support our proposal that, although the vagus nerve has been 
considered paradigmatic for parasympathetic modulation of blood pressure28, it also activates 
the splenic nerve under hypertensive challenges. This previously unknown aspect of 
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hypertension may indicate that completely different pathophysiological conditions, such as 
sepsis and hypertension, can affect the same neuro-immune connection. 
 
7nAChR at the intersection of the vagus and splenic nerves 
Mammals regulate synaptic transmission across sympathetic and parasympathetic ganglia 
via nicotinic acetylcholine receptors (nAChR), which can assemble in various stoichiometries 
and therefore have many functions29. One nAChR, the 7 subunit, can form homomeric 
pentamers that mediate excitatory postsynaptic currents. Interestingly, 7nAChR also 
participates in the cholinergic anti-inflammatory reflex and, though initially discovered as a 
modulator of macrophage function, has been shown to couple the vagus-splenic connection 
at the neuronal level25,26. Yet 7nAChR is not required for the parasympathetic modulations 
exerted by the vagus nerve in typical cardiovascular parameters such as heart rate30. To our 
surprise, 7nAChR KO mice infused with AngII had significantly inhibited SSNA firing 
frequency (Fig. 5a–d), which suggests the drive was hampered before reaching the splenic 
nerve. As observed in vagotomized mice, AngII infusion did not alter SSNA amplitude gain 
in 7nAChR KO mice (Fig. 5e). It may be that different SNA patterns can evoke different 
neurotransmitter responses10. Because the AngII-infused vagotomized and 7nAChR KO 
mice showed the vagus-splenic connection affects firing frequency but not amplitude gain, 
we asked which pattern is relevant for noradrenaline release in the spleen. Since AngII 
increases noradrenaline in the spleen through the activation of tyrosine hydroxylase7, we 
examined this response in AngII-infused 7nAChR KO mice and found that both 
noradrenaline content (Supplementary Fig. 6a) and tyrosine hydroxylase staining 
(Supplementary Fig. 6b) were significantly inhibited as compared with WT mice. In particular, 
the adrenergic fibers typically innervating the marginal zone of the spleen, evidenced by the 
CD169 antigen, were almost absent in 7nAChR KO mice (Supplementary Fig. 6b). Further, 
AngII challenge in 7nAChR KO mice produced neither the increased blood pressure 
typically observed in WT mice (Fig. 6a,b) nor the expected T cell egression (Fig. 6c,d). 
Overall, these data support the existence of a vagus-splenic nerve connection that is 








Figure 5: 7nAChR is necessary to the activation of SSNA on hypertensive 
challenges. (a–c) The representative raw signals of SSNA in a time bin (a) and in 
an enlarged particular of 10 s (b) show that 7nAChR KO mice have a reduced 
response to AngII infusion, as compared with WT controls. Residual SSNA during 
postmortem (lower panel in a) and blood pressure monitoring (c) are shown as well. 
(d) Analysis of firing frequency confirmed the reduced activity of 7nAChR KO mice 
on AngII infusion (WT and 7nAChR KO nmice=7; independent samples Student’s t-
test, t(12)=3.493, **P<0.01). (e) Accordingly to what observed in VagX, the mean 
amplitude gain of spikes induced by AngII was unaffected in 7nAChR KO, showing 
levels comparable to that of WT mice (WT and 7nAChR KO nmice=7; independent 





Figure 6: 7nAChR KO mice are protected from AngII-induced hypertension 
and T cell egression. (a,b) 7nAChR KO mice were protected from hypertension 
induced by chronic AngII infusion (nmice=8 for each group; two-way ANOVA for 
repeated measures; (a) SBP, F(interaction)=5.331, ***P<0.001; (b) DBP, 
F(interaction)=5.087, ***P<0.001). (c) Ablation of 7nAChR was effective in blocking 
T cell egression on AngII, similarly to vagotomized mice, as evidenced by the area 
of white pulp, labelled by CD3+ cells (magenta), delimited by B220+ cells (green) of 
the red pulp (scale bar, 200 μm). (d) Graph showing the relative quantitative analysis 
(nmice=7 WT vehicle; 8 WT AngII; 6 7nAChR KO Vehicle; 6 7nAChR KO AngII; 
two-way ANOVA, F(interaction)=8.939, *P<0.05 and ***P<0.001). 
 
Splenic nerve ablation prevents immune activation on AngII 
To define the relationship between SSNA and blood pressure rising in response to 
hypertensive stimuli, we established a procedure to denervate selectively splenic nerves 
(SDN) by thermoablation (Fig. 7a). Our first step was to verify that the procedure itself would 
not damage the artery. Ultrasound Doppler imaging revealed that SDN did not affect the 
normal pulse wave of the splenic artery (Fig. 7b). Moreover, microCT angiography after 
splenic denervation showed splenic artery integrity and consequently normal perfusion of the 
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spleen (Fig. 7c,d). To evaluate SDN efficacy, we injected a retrograde neurotracer into the 
spleen to label coeliac ganglion neurons (Fig. 8a). This procedure confirmed interrupted 
nerve trafficking between the central nervous system and spleen. In addition, tyrosine 
hydroxylase innervation was markedly reduced in the splenic arteries of SDN mice, as 
compared with sham (Fig. 8b), as was splenic noradrenaline (Fig. 8c). To demonstrate the 
selectivity of the procedure for the splenic nerve, we measured ipsilateral kidney 
noradrenaline content, which was comparable in SDN and sham mice (Fig. 8d), thereby 





Figure 7: Establishment of a procedure for selective splenic denervation. a) 
Example of surgical procedure for selective SDN, showing the splenic artery before 
(upper panel) and after (lower panel) denervation in a representative animal. (b) 
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Ultrasound Doppler imaging showing a normal pulse wave of the splenic artery in 
splenic denervated mice, comparable to that of sham. Colour Doppler also indicate 
a normal perfusion of the spleen after denervation. (c) Anatomical transversal 
reconstruction of microCT angiography evidencing of correct uptake of the contrast 
agent in the spleen. (d) 3D reconstruction demonstrating integrity of splenic artery 




Figure 8: Selective splenic denervation blocks sympathetic nervous system in 
the spleen. (a) Coeliac ganglion neurons, labelled with a retrograde neurotracer 
injected in the splenic parenchyma, are significantly reduced in SDN mice as 
compared with sham controls. (nmice=6 for each group; scale bar, 200 μm). (b) 
Significant reduction of tyrosine hydroxylase immunofluorescence in splenic artery 
of two representative SDN as compared with Sham mice (nmice=6 for each group; 
scale bar, 50 μm). (c) Noradrenaline levels were significantly reduced in the spleen 
of SDN mice as compared with Sham mice (Sham and SDN groups nmice=8; 
independent samples Student’s t-test, t(14)=10.606, ***P<0.001). (d) Analysis of 
noradrenaline content in the ipsilateral kidney was unaltered in SDN mice as 
compared with Sham, revealing no off-target effect of the procedure (Sham and SDN 







Figure 9: Splenic denervation protects from hypertension and T cell egression 
from spleen. (a,b) Mice with splenic denervation were protected from AngII-induced 
hypertension, as compared with Sham mice and SDN mice with vehicle alone 
(Sham-vehicle, Sham-AngII and SDN-vehicle nmice=10; SDN-AngII nmice=11; two-
way ANOVA for repeated measures; (a) SBP, F(interaction)=6.723, ***P<0.001; (b) 
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DBP, F(interaction)=3.070, ***P<0.001). (c) Mice with splenic denervation are 
protected from the T cell egression induced by AngII, as evidenced by the area of 
CD3+ cells (magenta), recognizing white pulp and delimited by B220+ cells (green) 
delineating red pulp (nmice=5 for each group; scale bar, 200 μm). (d) Graph showing 
the relative quantitative analysis (nmice=5 for each group; two-way ANOVA, 
F(interaction)=46.384, ***P<0.001). (e) AngII fails to induce co-stimulation of T cells 
in mice with splenic denervation, as evidenced by reduced CD86+ cells (green) 
expression in the marginal zone of the spleen, labelled by CD169+ cells (magenta) 
(nmice=5 for each group; scale bar, 50 μm). 
 
 
Next, we infused SDN and sham mice with AngII for 28 days using osmotic minipumps to 
elevate sympathetic nervous system activation in the spleen, as shown by increased tyrosine 
hydroxylase staining (Supplementary Fig. 7a). SDN mice were protected from elevated 
sympathetic nervous system activity in the marginal zone of the spleen, delineated by the 
CD169 antigen (Supplementary Fig. 7a). More importantly, SDN mice were significantly 
protected from the increased blood pressure induced by chronic AngII that is typically 
observed in sham mice (Fig. 9a,b; Supplementary Fig. 7b,c). Similar results were obtained 
with both radiotelemetry (Supplementary Fig. 7b,c) and tail-cuff measurements (Fig. 9a,b). 
We then asked whether this effect could be due to a modulating function of SSNA on splenic 
T cells, which are known to be activated by hypertensive challenges, before deployment 
toward target organs5,6,7. SDN hampered AngII-induced T cell egression from the splenic 
reservoir, as shown by the total CD3+ T cell content and area in the white pulp (Fig. 9c,d). 
Indeed, AngII infusion did not reduce T cell content in mice with SDN but did in sham mice 
(Fig. 9c,d). We also evaluated whether the lack of T cell egression could be caused by failed 
T cell co-stimulation activation in the absence of an intact splenic nerve. Mice with SDN were 
protected from AngII-induced CD86 expression (Fig. 9e), the typical hallmark of T cell co-
stimulation and hence a key indicator of full activation for target organ colonization in 
hypertension6,7. We next assessed T cell infiltration in target organs by flow cytometry and 
found that AngII-SDN mice were significantly protected from CD8+ T cell infiltration in the 
aorta (Fig. 10a) and kidneys (Fig. 10b,c) in terms of both total cells and the number of cells 
primed with markers for homing (CD8+ CD44+ cells) and activation (CD8+ CD69+ cells). 
Similar results were found for CD4+ T cell infiltrates (Fig. 10a–c). These data were also 
confirmed by immunohistochemical analyses of the aorta (Supplementary Fig. 8a–d) and 














Figure 10: Splenic denervation protects from the T cells infiltration in target 
organs of hypertension. (a,b) Flow cytometry analysis shows that SDN mice were 
protected from the AngII-induced increase of total CD8+ and CD4+ T cells (upper 
panels) in aorta (a) and (b) kidneys. SDN mice displayed also a reduced amount of 
cells positive for homing (CD44) and activation (CD69) antigens (middle and lower 
panels, respectively) (nmice=9 for each group). Significance of two-way ANOVA was 
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as follow for aortas: CD8 F(interaction)=7.922, CD8-CD44 F(interaction)=5.071, 
CD8-CD69 F(interaction)=7.344, CD4 F(interaction)=9.122, CD4-CD44 
F(interaction)=7.867, CD4-CD69 F(interaction)=8.432. Significance of Two-way 
ANOVA was as follow for kidneys: CD8 F(interaction)=13.88, CD8-CD44 
F(interaction)=5.382, CD8-CD69 F(interaction)=7.202, CD4 F(interaction)=6.248, 
CD4-CD44 F(interaction)=3.810, CD4-CD69 F(interaction)=10.89. *P<0.05, 





Our results demonstrate that hypertensive challenges exploit a cholinergic-sympathetic drive, 
realized through a vagus-splenic nerve connection, to activate the T cells that eventually 
migrate to target organs and contribute to blood pressure regulation. We show that stimuli 
like chronic AngII and DOCA, which are sensed by the circumventricular organs in the brain 
to induce hypertension19,23, activate potent splenic nerve discharge. We also report that 
SSNA depends on an intact vagus nerve efferent that terminates in the coeliac plexus ganglia 
where the catecholaminergic fibres of the splenic nerve originate. We further demonstrated 
that the vagal-coeliac-splenic nerve connection regulating blood pressure is mediated by 
7nAChR, similar to dynamics previously described in endotoxemia26. Taken together, our 
findings—particularly our selective denervation of the splenic nerve—have important 
translational implications. Mice with splenic denervation were protected from hypertension 
through impeded T cell activation, egression from the spleen and consequent infiltration of 
target organs. These results provide a rationale for investigating novel therapeutic strategies 
based on splenic denervation to treat hypertension. 
Historically recognized as a crucial player in hypertension, the sympathetic overdrive 
promotes the initial blood pressure surge in the early clinical stages of the disease and helps 
maintain elevated blood pressure levels3,10. Moreover, constant adrenergic overactivation is 
known to contribute, over time, to end-organ damage caused by chronic hypertension and 
metabolic abnormalities often observed in hypertensive patients. Researchers have sought 
to understand the mechanisms and effects of renal sympathetic nerves in hypertension31. 
Indeed, it is now widely accepted that, under hypertensive conditions, this system changes 
in pathological ways that contribute to alterations in sodium reabsorption and thus negatively 
influence blood pressure control3,10,31. Yet the results of clinical trials on renal denervation 
remain controversial11,12,13, lending support to the hypothesis that there may be other 
mechanisms contributing to the impact of constant sympathetic overactivation in 
hypertension. Hence, we sought to pursue selective splenic denervation to decipher the 
immune system’s role in hypertension. Although a simple neurectomy could in principle prove 
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the same concepts and provide results, selective denervation obtained by thermoablation 
has clinical potential for patients for whom the renal denervation has failed. Our results 
strongly suggest splenic denervation may be a useful tool in treating resistant hypertension 
in humans. 
Abundant research has confirmed that the immune system plays a key role in hypertension. 
Yet the process by which a hypertensive challenge signals the immune system has remained 
largely unclear. Intriguingly, even as researchers in the field of hypertension began dissecting 
the role of the immune system, immunologists of the same period discovered that neural 
circuits can modulate immune cells15,32. Meanwhile, decades of studies focusing on the 
neurophysiological basis and broader effects of the inflammatory reflex converged on the 
spleen. Action potentials are transmitted from the vagus nerve to the coeliac ganglion, where 
the splenic nerve originates, and activated adrenergic splenic neurons can regulate a specific 
T cell subset in splenic white pulp. In the spleen, we now know, neural signals deal with 
immunity directly33,34. We are beginning to understand the complex relationship between the 
nervous system and immunity. 
As researchers continue to decipher these connections, nervous circuits’ largely undiscussed 
role in blood pressure regulation10 will become increasingly important. On the basis of our 
results, it is tempting to speculate that sympathetic overactivity in hypertension has effects 
beyond the kidney and baroreflexes. The novel concept that the autonomic nervous system 
can have long-term effects on cardiovascular pathologies through immune system regulation 
requires us to significantly rethink the role of the autonomic nervous system14. Interestingly, 
it is well known that immune organs, and particularly the spleen, are directly innervated by 
the sympathetic nervous system7,35. In addition, the autonomic system may be a powerful 
regulator of immunity: although AngII has been shown to be responsible for a variety of 
actions that may contribute to the development of hypertension, several milestone papers 
demonstrate that AngII also activates the peripheral sympathetic nervous system and affects 
immune responses19. Intracerebral ventricular AngII infusion increases central sympathetic 
nerve activation and enhances the immune response in the periphery36. These findings are 
particularly important because they demonstrate that AngII-induced effects on both 
hypertension and immune system activation are not caused by direct AngII influence on the 
vasculature and immune cells, thus suggesting that central signals may be integrated by the 
immune system to drive hypertension. 
We believe the results presented in this paper are significant because they reveal, for the first 
time, a previously unknown sympathetic pathway in hypertension. The brain-to-spleen 
connection’s realization through a cholinergic-sympathetic nervous drive resembles the 
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cholinergic anti-inflammatory pathway that is protective when activated by electrically 
stimulating the vagus efferent during endotoxemia24,25,26,27. So far, this pathway has been 
primarily considered a way for the nervous system to modulate immune response to bacterial 
toxins. More specifically, vagus stimulation during septic shock determines the coupling of 
cholinergic pre-ganglionic neurons and postganglionic sympathetic nerves, linkages that are 
ultimately responsible for attenuating splenic TNF production24,25,26,27. 
7nAChR has been well characterized as the molecular mediator of the cholinergic anti-
inflammatory pathway and therefore integral to the vagus nerve/sympathetic drive in the 
splenic district26,34. Indeed, 7nAChR can be found in several tissues, including the brain, 
ganglia, immune cells and so on. Our experiments showed that 7nAChR KO mice are 
protected from AngII-induced hypertension. Because 7nAChR is a demonstrable mediator 
of the cholinergic anti-inflammatory pathway expressed in cytokine-producing splenic 
macrophages25,34 but also integrates the sympathetic and parasympathetic systems in 
presynaptic neurons of the splenic nerve26, we sought to understand where 7nAChR acts 
in hypertension. That 7nAChR KO mice had markedly inhibited AngII-elicited SSNA 
supported the idea that 7nAChR plays a role in mediating autonomic integration among 
parasympathetic and sympathetic drives in the coeliac ganglion (upstream from the splenic 
sympathetic drive). Interestingly, vagus nerve stimulation was recently shown to mediate 
protection from kidney ischemia-reperfusion injury through 7nAChR in splenocytes37. Lastly, 
our findings highlight the possibility that cholinergic anti-inflammatory pathway activation 
during endotoxemia may be also hemodynamic and therefore relevant to fighting the 
hypotensive shock that is one of the fatal complications of sepsis. 
 
Methods 
Animals and drugs 
All animal handling and experimental procedures were performed according to European 
Community guidelines (EC Council Directive 2010/63) and the Italian legislation on animal 
experimentation (Decreto Legislativo D.Lgs 26/2014). All efforts were made to minimize 
suffering, and the principles of Replacement, Reduction and Refinement (that is, the ‘three 
Rs’) were applied to all experiments. 
C57Bl/6J male mice, aged 8-12 weeks, were purchased from Jackson Laboratory and used 
in all experiments. Chrna7 (7nAChR) knockout and WT littermates (stock number 003232, 
Jackson Laboratory) were used where indicated. Mice were housed in an air-conditioned 
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room (temperature 21±1 °C, relative humidity 60±10%), with lights on from 06:00 to 18:00, 
and had sawdust as bedding, pellet food and tap water ad libitum. After surgical procedures, 
mice were housed in recovery boxes (temperature 37 °C) and carefully monitored for several 
days. 
In acute treatments administered during electrophysiological recordings, mice received 
Sodium Nitroprusside (SNP; Sigma Aldrich), Phenylephrine (Phe; Sigma Aldrich) and 
Hexamethonium bromide (Sigma Aldrich) at the dosage indicated in the appropriate section. 
A cohort of mice received 0.5 mg kg−1 day−1 of AngiotensinII (AngII; Sigma Aldrich) or Vehicle 
(NaCl 0.9%), delivered subcutaneously with osmotic minipumps (model 2004, ALZET)7. 
Another group of mice underwent subcutaneous implantation of a 50 mg pellet of DOCA or 
placebo as control (Innovative Research of America) without uninephrectomy23. Mice were 




In the first set of experiments, SSNA was recorded in mice at maximum blood pressure 
response to either sodium nitroprusside or phenylephrine, and in the next set of experiments, 
SSNA was recorded three days after receiving either AngII or DOCA-salt. Mice infused with 
vehicle or implanted with a placebo pellet were used as respective controls. Mice were 
anaesthetized with 5% isoflurane and subsequently maintained with 1.5–2% (supplemented 
with 1 l min−1 oxygen). Blood pressure was monitored during the entire experiment with a 
single-pressure catheter (Millar, SPR-100) inserted in the left femoral artery and connected 
to a pressure transducer (Millar, MPVS ULTRA)7. Body temperature was maintained between 
37 and 38 °C by a homoeothermic blanket. 
An abdominal incision was made and the intestinal tract was carefully moved aside to expose 
the splenic artery. First, the splenic artery was isolated, and then the splenic nerve was 
carefully separated from surrounding tissue. A bipolar stainless steel electrode (MLA1214 
Spring Clip Electrodes, ADInstruments) was adjusted to the nerve size and gently placed on 
the splenic nerve, according to previously described procedures20,21,22,38. The ground wire 
was plugged into mouse soft tissues. When optimum recording was obtained, the electrode 
was covered with silicone gel. SSNA was recorded from the implanted electrode continuously 
during the next 2 h, as was arterial blood pressure. Mice were then killed by isofluorane 




The splenic nervous signal was amplified (gain × 10,000) and then sampled at 4 kHz with a 
digital amplifier (Animal Bio Amp; ADInstruments). The raw signal was filtered at 300–1,000 
Hz and expressed as V. Background noise estimates for the nerve activity trace were based 
on postmortem recording. Raw splenic nerve activity and blood pressure signals were 
monitored using a PC that was online during the entire recording. Operators were blinded to 
the experimental group during recording. 
Data were collected using a Power Lab data acquisition system and analyzed with Lab Chart 
7 (Spike Analysis Module). Typically, a sympathetic burst was identified as a signal above 
the threshold determined by the background noise of the postmortem recording. In acute 
experiments, SSNA counting was measured using a bin time of 5 min at the plateau of blood 
pressure response after a bolus of sodium nitroprusside (2.5g g−1 of body weight in a volume 
of 25 l of saline followed by 50 l of saline) or phenylephrine (20 μg g−1 of body weight in a 
volume of 25 l of saline followed by 50l of saline)20. Background noise was recorded after 
ganglionic blockade with hexamethonium20 (50 g g−1 of body weight in 25l) and during 
postmortem. In chronic experiments, SSNA counting was performed using a bin time of 10 
min and collected every 20 min. Firing frequency was measured as the mean value of total 
number of spikes in a time bin. The amplitude gain was calculated as the ratio between mean 
spike amplitude and spike identification threshold in a time bin. 
 
Vagotomy 
Surgical cervical unilateral vagotomy was performed via a cervical midline incision that 
exposed the left vagus trunk, which was cut with forceps. Coeliac vagotomy was performed 
with the same procedure, cutting the distal end of the coeliac branch of the vagus nerve. In 
a first set of experiments, both procedures were executed while recording SSNA. Vagus 
nerve was exposed while preparing the mouse for the electrophysiological recording. After 
the acquisition of two SSNA time bins, the cervical or coeliac vagus nerve was transected, 
while SSNA recording continued for at least two additionally time bins. In a second group of 




After anaesthesia with isoflurane (2–5 Vol%), supplemented with 1 l min−1 oxygen, the mouse 
abdominal cavity was opened and the splenic artery was carefully exposed. The selective 
SDN was performed by thermoablation applied with a thermal cautery (GEIGER Medical 
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Technologies). The cautery was gently placed on the splenic artery for 5–6 s until the splenic 
artery was dilated. In sham-operated mice, the abdomen was opened and the splenic artery 
was exposed, but thermoablation was not performed. 
 
Neurotracer injection 
The efficacy of splenic nerve ablation was evaluated by neuronal labelling, obtained by 
retrograde transport, in coeliac ganglion. Mice were anaesthetized with isoflurane (2–
5 Vol%), the spleen was exposed through a left flank incision and 10 injections of 2 l 
hydroxystilbamidine, methanesulfonate 2% (Molecular Probes, H22845) were injected into 
the parenchyma7. Mice were allowed to recover, and seven days later they were deeply 
anaesthetized so that coeliac ganglia from each side could be collected. 
 
Blood pressure measurements 
Arterial blood pressure was monitored by radiotelemetry where indicated. HD-X11 pressure 
transmitters (Data Sciences International) were implanted in mice anaesthetized with 
isofluorane. The pressure-sensing catheter was inserted into the aortic arch, and the 
transmitter body was placed in a subcutaneous pouch on the back. Following surgery, the 
mice were allowed to recover for at least 1 week. Radio signals from the implanted transmitter 
were captured by the Physiotel RPC-1 receiver (Data Sciences International), and the data 
were stored online using the Dataquest Ponemah 4.9 data acquisition system (Data Sciences 
International) according to standardized procedures7,39,40. BP was recorded daily for 2 h 
(10am-12pm) to monitor the effects of AngII. 
Noninvasive blood pressure measurement was performed by tail-cuff plethysmography (BP-
2000 Series II, Visitech Systems) in conscious mice daily for 2 hours (10 am–12 pm)7,39,40. 
Operators were blinded to the experimental group during blood pressure monitoring. 
 
In vivo imaging 
Ultrasound analysis was performed with Vevo 2100 (VisualSonics, Toronto, Canada) 
equipped with 40MHz transducer, as previously described7. Mice were anaesthetized with 
isoflurane anaesthesia system (5 Vol% induction, 1.5 Vol% maintenance supplemented with 
1 l min−1 oxygen) and taped to a warmed bed, positioned on the right side. The spleen area 
was shaved, and the probe was positioned under the chest to get a longitudinal view of the 
spleen. To visualize splenic artery perfusion and function after splenic denervation, PW 
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Doppler was applied in order to measure peak flow velocity. Colour Doppler was applied to 
images of the spleen to verify organ perfusion after splenic denervation. 
MicroCT scanning was performed with SKYSCAN 1178 (SKYSCAN, Kontich, Belgium), as 
previously described7. The tube parameters were set to 50 kV and 615 A, exposure 480 ms, 
with a rotation step of 0.360°. Mice were anaesthetized with ketamine-xylazine and positioned 
on the bed. Two different scans were performed: the first scan occurred immediately after 
contrast agent injection (ExiTron nano 12,000, 100 l per mouse) to determine vascular 
perfusion; after 24 h, the second scan was performed to obtain a spleen tissue image using 
contrast agent accumulation in the spleen. Spleen reconstruction was performed with 3D 
Slicer41. In both scans, the image was cropped to the spleen region, then the images were 
co-registered with an affine transformation. The co-registered images were labelled and 3D 
rendered to highlight the vascularization in the first scan (shown in red) and contrast tissue 
absorption (shown in green) in the second scan. 
 
Tissue isolation 
At the end of each experiment, tissues were isolated for subsequent analyses. The splenic 
artery was isolated and fixed with 4% paraformaldehyde (PFA). Spleen and aorta were 
collected and embedded in OCT for cryo-sectioning. Kidneys were explanted and embedded 
in paraffin for immunohistochemistry. Coeliac ganglion was post-fixed in Zamboni’s Fixative 
and embedded in OCT for cryo-sectioning. For biochemical analyses, spleen and kidneys 
were explanted and flash-frozen in liquid nitrogen. 
 
Flow cytometry 
After mice were exsanguinated, both kidney and aorta were collected. Kidney cell suspension 
was obtained by mechanically disrupting two decapsulated kidneys in 10 ml of RPMI 1640 
medium (GIBCO, Invitrogen) supplemented with 5% FBS, which was then passed through a 
70 m sterile filter (Falcon, BD). The resulting cell suspension was centrifuged at 300g for 10 
min to pellet the cells. To isolate leukocytes from cell suspension, the pellet was suspended 
in 36% Percoll (Sigma), gently overlaid onto 72% Percoll and centrifuged at 1,000g for 30 
min at RT. Cells were isolated from Percoll interface and washed twice in medium at 300g 
for 10 min at 4 °C. Aorta cell suspension was obtained by mechanically disrupting the tissue 
and digesting the suspension in Digestion Cocktail (450 U ml−1 Collagenase I, 125 U ml−1 
Collagense XI, 60 U ml−1 Hyaluronidase I-S) for 40 min at 37 °C with gentle vortexing. Cell 
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suspension was then passed through a 70 m sterile filter (Falcon, BD), and the resulting cell 
suspension was centrifuged at 300g for 5 min to pellet the cells. 
Lymphocytes from both organs’ leukocytes were enriched with Mouse T Lymphocyte 
Enrichment Set-DM (BD IMag), and the number of the cells was assessed using trypan blue 
and an automated counter (Countess, Life Technologies). Total kidney and aorta 
lymphocytes were analyzed with flow cytometry. First, samples were pre-incubated with anti 
CD-16/32 Fc receptor and then incubated with various combinations of mAbs for 
immunofluorescence staining using BD FACSCanto (BD Biosciences). The fluorochrome-
conjugated mAbs to mouse antigens used for flow cytometry analysis were as follows: 
PerCP-Cy5.5 anti-CD8a (53-6.7), FITC anti-CD4 (RM4-5), APC anti-CD69 (H1.2F3), APC-
Cy7 anti-CD45 (30-F11), PE-Cy7 anti-CD44 (IM7) (1:100; BD PharMingen). The data were 
analyzed using FlowJo Software (V 10.0.8). 
 
Immunofluorescence analysis 
Splenic arteries used for immunofluorescence analysis were fixed with 4% PFA, passed in 
PBS for incubation with antibodies and then coverslipped with anti-fading medium (DABCO, 
Fluka). For coeliac ganglion and spleen, 25 m sections were obtained with cryostat 
microtome. Coeliac ganglions were directly mounted and coverslipped for analysis of neurons 
labelled with retrograde fluorescent neurotracer. Slides from the spleen were post-fixed in 
PFA (4%) for 15 min and processed for staining. 
The following primary antibodies were used: Sheep anti-tyrosine hydroxylase (1:800; 
AB1542, Millipore); Rat anti-CD169 (1:200; MCA884, Serotec); Hamster anti-CD3 (1:100; 
MCA269OT, Serotec); Rat anti-CD45R/B220 (1:50; 550286, BD Pharmigen); Rabbit anti-
CD86 (1:100; NB110-55488, Novus Biologicals). Sections were incubated with their 
respective secondary antibodies conjugated to Alexa Fluor 488 or Cy3 (1:200; Jackson 
Immunoresearch). Slides were then coverslipped with DAPI-containing medium (Vector). 
All coverslipped, mounted tissue sections were scanned using a Zeiss 780 confocal laser-
scanning microscope, as previously described7. A 405 Diode laser was used to excite DAPI; 
a 488 nm argon laser to excite Alexa Fluor 488 and a 543 HeNe to excite Cy3. Quantitative 





Kidney sections were deparaffinized and rehydrated before undergoing antigen retrieval. 
Aortas, embedded in OCT, were post-fixed with PFA (4%) for 15 minutes. Slides were 
processed with the primary antibodies anti-CD8 (1:50; 550286, BD PharMingen) and anti-
CD4 (1:50; 550280, BD PharMingen). Samples were incubated with biotinylated secondary 
antibodies (1:200; Vector) and then processed with DAB (Vector). Hematoxylin (Sigma 
Aldrich) was used for counterstaining. The number of CD8+ and CD4+ cells per m2 was 
determined using the Image J software Cell Counter plugin analysis tool (NIH). All images 
were captured using a DMI3000B Leica optical microscope provided by Leica Cameras 
(Leica Microsystems) and processed with the Leica Application Suite (LAS V3.3). 
 
ELISA for noradrenaline assay 
Noradrenaline levels were measured in duplicate for each spleen and kidney sample. 
Samples were extracted with a buffer containing 0.1 HCl and 1 mM EDTA and assayed using 
a high-sensitivity ELISA kit (RE59261, IBL International), following the manufacturer’s 
instructions. Results are expressed as nmol mg−1 of wet tissue. 
 
Statistical analysis 
All the experiments were replicated within the laboratory. Sample size was pre-estimated 
from the previously published research and from pilot experiments performed in the 
laboratory. Data are presented as mean±s.e.m. Data distribution was assessed with the 
Shapiro–Wilk normality test and D’Agostino Pearson test, and assumption of homogeneity of 
variance was tested using Levene’s test of equality of variances. For amplitude gain analysis, 
unequal variance between groups was observed in a minority of cases, and a Welch 
correction was performed for all comparisons. Statistical significance was assessed with the 
appropriate test according to each experimental design, as detailed in figure legends. After 
confirming that all data had normal distributions, we applied Student t-test for either 
independent samples or paired samples, according to the experimental design and as 
specified in the figure legends. Multiple group analysis was performed with two-way ANOVA 
followed by Bonferroni’s post hoc. Analysis for repeated measures was applied when 
required by the experimental setting. P<0.05 was considered significant. Statistical analyses 
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Abstract 
Aims. Chronic increase of mineralocorticoids obtained by administration of 
Deoxycorticosterone acetate (DOCA) results in salt dependent hypertension in animals. 
Despite the lack of a generalized sympathoexcitation, DOCA-salt hypertension has been also 
associated to overdrive of peripheral nervous system in organs typically targeted by blood 
pressure (BP), as kidneys and vasculature. Aim of this study was to explore whether DOCA-
salt recruits immune system by overactivating sympathetic nervous system in lymphoid 
organs and whether this is relevant for hypertension. 
Methods and results. To evaluate the role of the neurosplenic sympathetic drive in DOCA-
salt hypertension, we challenged splenectomized mice or mice with left coeliac 
ganglionectomy with DOCA-salt, observing that they were both unable to increase BP. We 
next evaluated by immunofluorescence and ELISA the levels of PlGF upon DOCA-salt 
challenge, which significantly increased the growth factor expression but only in the presence 
of an intact neurosplenic sympathetic drive. When PlGF KO mice were subjected to DOCA-
salt, they were significantly protected from the increased BP observed in WT mice under 
same experimental conditions. In addition, absence of PlGF hampered DOCA-salt mediated 
T cells co-stimulation and their consequent deployment toward kidneys where they infiltrated 
tissue and provoked end-organ damage. 
Conclusion. Overall our study demonstrates that DOCA-salt requires an intact sympathetic 
drive to the spleen for priming of immunity and consequent BP increase. The coupling of 
nervous system and immune cells activation in the splenic marginal zone is established 
through a sympathetic-mediated PlGF release, suggesting that this pathway could be a valid 






Deoxycorticosterone acetate (DOCA)-salt hypertensive challenge in mice resembles a 
condition of salt sensitivity, observed in some hypertensive patients and often leading to 
increased susceptibility to higher BP1. Although polydipsia and increased metabolic rate 
induced by DOCA-salt were considered as major culprits of the resulting hypertensive 
phenotype, a large body of researches focused the attention on the brain-mediated effects of 
DOCA-salt2,3. It has been reported that the DOCA-salt model, optimal to reproduce low 
circulating levels of renin–angiotensin system (RAS) activity4, determines instead a 
concomitant elevation of brain RAS activity5-7, thus suggesting the existence of a brain-
mediated overactivation of peripheral sympathetic tone. On a different note, it has been 
reported that DOCA-salt hypertension depends on the activation of adaptive immunity, in a 
way similar to that observed for angiotensin (AngII)8. Thus, despite different in the etiology, 
AngII and DOCA-salt need mobilization of activated T cells, directed toward target organs of 
hypertension, particularly to kidneys9. While lots of studies focused on immune mechanisms 
activated during DOCA-salt challenge and participating in the establishment of hypertensive 
disease9-12, less is known about how the neurogenic effect of DOCA-salt connects to priming 
of immunity. In a previous study we found that the angiogenic Placental Growth Factor 
(PlGF), belonging to vascular endothelial growth factors family (VEGFs), mediates the 
neuroimmune coupling established in the spleen upon chronic AngII, playing a central role in 
the increase of BP13. It has been described that the activation of RAS activity in the brain 
exerted by AngII and acting through the AngII type 1 receptors (AT1Rs)14, was similarly 
activated by DOCA-salt challenge7, 15. In particular it has been shown that, despite lesions of 
the Subfornical Organ (SFO), a circumventricular organ acting as a sensory brain structure, 
were not able to prevent DOCA-salt effects on BP16, a highly selective deletion of AT1aRs in 
this area attenuated fluid intake and blunted the hypertensive response7. Overall these data 
support the concept that the two hypertensive challenges, despite different in their nature, 
recruit a common pathway in the brain, which in turn recruit the hypertensive disease. In the 
most classical meaning, the activation of this pathway in the brain mediates the typical 
overactivation of the sympathetic nervous system (SNS) in peripheral districts typically 
controlling BP levels, like kidneys an vasculature17. More recently, we also showed that both 
AngII and DOCA-salt enhanced the sympathetic activity of the splenic nerve (SSNA) through 
a brain-vagus-splenic circuit18. However, it is still unknown whether the two hypertensive hits, 
with different peripheral mechanisms of action, share common neuroimmune mechanisms in 
the onset of hypertension. Here we tested the hypothesis that PlGF could mediate DOCA-






All the experimental procedures were performed according to European Communities 
guidelines and the Italian legislation on animal experimentation (Decreto L.vo 26/14). The 
protocol was approved by the Italian Ministry of Health and by our Institutional Committee. 
PlGF knock-out (KO) mice were backcrossed for 11 generations in C57Bl/6J mice from the 
original strain in 50% 129Sv/50% Swiss mice19. Wild-type (WT) mice with the same genetic 
background (C57Bl/6J) were obtained from the KO colony and used as the appropriate 
control strain. Where indicated, C57Bl/6J mice were used and directly acquired from Charles 
River. Under anesthesia with isoflurane (2–5 Vol% for induction and 1,5-2 Vol% for 
maintenance), supplemented with 1 L/min oxygen, PlGF KO and WT control mice or 
C57Bl/6J mice of 8-12 weeks were subcutaneously implanted with 50 mg of DOCA pellet 
with a release time of 21 days (Innovative Research of America), as previously described18. 
Control groups of both genotypes received the appropriate placebo pellet (Innovative 
Research of America). Mice with DOCA were maintained with tap water plus 0.15 mol/L 
(0.9%) NaCl (DOCA-salt), whereas mice with placebo received tap water alone. All mice were 
then fed with standard chow diet ad libitum. 
 
2.2 Blood Pressure measurements 
Arterial BP was measured by tail cuff and radiotelemetry, accordingly to previously described 
procedures13, 18, 20. Tail cuff plethysmography (BP-2000 Series II, Visitech Systems) was used 
to daily measure BP, between 8 am and 1 pm. For continuous BP monitoring with 
radiotelemetry, mice were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) 
i.p. and implanted with the pressure sensing catheter of a HD-X11 transmitter, inserted into 
the aortic arch (Data Sciences International), with the device placed in a subcutaneous pouch 
on the back of the mouse. After surgery, mice were individually kept in recovery cages 
(temperature 37 °C). Monitoring of BP started 1 week after surgery and data were recorded 
for 5 minutes every hour. The basal BP levels were registered for 3 days. Subsequently mice 
were treated with DOCA-salt or placebo, accordingly to the experimental groups, and BP was 
monitored for the following 21 days. Radio signals were transmitted to the Physiotel RPC-1 
receiver and data were acquired online by the Dataquest Ponemah 4.9 data acquisition 
system (Data Sciences International). Operators were blinded to the experimental groups 
during BP measurements. 
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2.3 Splenectomy and Left Coeliac Ganglionectomy  
C57Bl/6J mice were anesthetized with isoflurane (2–5 Vol% for induction and 1,5-2 Vol% for 
maintenance), supplemented with 1 L/min oxygen, to perform splenectomy or coeliac 
ganglionectomy (CGX) as previously described13. In brief, for splenectomy, the abdominal 
cavity of mice was opened and splenic vessels were cauterized, before careful removal of 
the spleen. Sham mice underwent the same surgical procedure to open the abdomen, but 
without removing the spleen. After surgery mice were individually placed in thermal cages for 
a recovery period, and then were implanted with DOCA-salt or placebo pellets. 
For CGX execution, mice underwent a midline laparotomy and, after the isolation of both 
aorta and coeliac artery, the left coeliac ganglion was gently removed. In the group of sham 
mice, both aorta and left coeliac artery were isolated and then the left coeliac ganglion was 
exposed but without removing it. After surgery, mice were individually placed in thermal cages 
for the process of recovery, after which mice were implanted with DOCA-salt or placebo 
pellets. The rate of mortality observed for both procedures ranged from 5% to 10% at 
maximum and was observable only during or immediately after surgery. In the post-operative 
period, mice were daily monitored to observe the eventual onset of adverse events, and if 
this was the case mice were sacrificed. 
 
2.4 Metabolic cages 
During the last week of DOCA-salt or placebo protocol, PlGF KO and WT mice were 
individually housed in metabolic cages (Tecniplast), allowing acclimatization before starting 
with sampling of urine and plasma. Body weight was measured before and after metabolic 
cage entry. Mice had free access to tap water added with 0.9% NaCl for DOCA-salt group 
whereas the placebo group of mice was maintained with tap water alone. Urine and plasma 
samples were used for assessment of analytes of interests with a clinical analyzer, 
accordingly to standard protocols. 
 
2.5 Immunofluorescence and immunohistochemistry 
For immunofluorescence analysis, the spleen was collected and embedded in OCT. The 
following primary antibodies were used as previously described13, 18 27 : rat anti-CD169 
(1:200; MCA884, Serotec) to identify metallophilic marginal zone macrophages; rat anti-ER-
TR7 (1:200; Acris) for fibroblast reticular cells;  hamster anti-CD3 (1:100; MCA269OT, 
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Serotec), labeling T cells; rat anti-CD45R/B220 (1:50; 550286, BD Pharmigen) to mark 
splenic B cells; rabbit anti-CD86 (1:100; NB110-55488, Novus Biologicals) for identifying 
mature antigen presenting cells (APC). Sections were incubated with the appropriate 
secondary antibodies conjugated to Alexa Fluor 488 (excitation wavelength 488 nm, emission 
wavelength 517 nm) or Cy3 (excitation wavelength 543 nm, emission wavelength 588 nm) 
(1:200; Jackson Immunoresearch). Slides were then coverslipped with a mounting medium 
containing DAPI (excitation wavelength 405, emission wavelength 453) (Vector laboratories). 
Tissue sections were scanned using a Zeiss 780 confocal laser scanning microscope. A 405 
Diode laser was used to excite DAPI; a 488 nm argon laser to excite Alexa Fluor 488 and a 
543 HeNe to excite Cy3. Quantitative analysis of white pulp area of the spleen was 
determined using Image J software (NIH), as previously described18.  
For renal damage assessment, kidneys were explanted and embedded in paraffin for 
immunohistochemistry. Sections of 4 m were deparaffinized and rehydrated before 
undergoing antigen retrieval. Slides were processed with the primary antibodies anti-CD8 
(1:50; 550286, BD Pharmingen) and anti-CD4 (1:50; 550280, BD Pharmingen) and then 
incubated with biotinylated secondary antibodies (1:200; Vector laboratories) and processed 
with DAB (Vector laboratories). Hematoxylin (Sigma Aldrich) was used for nuclei 
counterstaining. The number of CD8+ and CD4+ cells per m2 was determined using the 
Image J software Cell Counter plugin analysis tool (NIH), as previously described13,18. 
Analyses of renal damage were performed in tissue sections stained with Picrosirius Red, 
Masson’s Trichrome and periodic acid–Schiff (PAS). Images of kidney sections were used to 
calculate the size of renal corpuscle, glomerular area and Bowman’s capsule, and the 
percentage of renal fibrosis, all by using Image J software (NIH). 
All images were captured using a DMI3000B Leica optical microscope provided by Leica 
Cameras (Leica Microsystems) and processed with the Leica Application Suite (LAS V3.3). 
 
2.6 ELISA for determination of metabolites 
PlGF protein levels were determined by a high sensitivity ELISA kit (R&D Systems), as 
previously described13. Flash frozen splenic tissues were extracted with a buffer containing 
PBS and protease inhibitor cocktail (Sigma Aldrich). Results were expressed as pg of PlGF 
for mg of wet tissue. Noradrenaline levels were measured by a high sensitivity ELISA kit (IBL 
International), as previously described18. Flash frozen splenic and renal tissues were 
extracted with a buffer containing 0.1N HCl and 1mM EDTA. Results were expressed as nmol 
of noradrenaline for mg of wet tissue. 
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2.7 Flow cytometry 
After mice were exsanguinated, both kidneys were collected. Cell suspensions were obtained 
by mechanically disrupting two decapsulated kidneys in 10 ml of RPMI 1640 medium 
(GIBCO, 13 Invitrogen) supplemented with 5% FBS, which was then passed through a 70 
μm sterile filter (Falcon, BD Biosciences). The resulting cell suspension was centrifuged at 
300g for 10 min to pellet the cells. 
To isolate leukocytes, the pellet was processed as previously described13,18 and lymphocytes 
were enriched from total cell suspension with Mouse T Lymphocyte Enrichment Set-DM 
(IMag BD Bioscience), and the number of the cells was assessed using trypan blue and an 
automated counter (Countess, Life Technologies). Cells were analyzed by flow cytometry 
staining with the following mix of antibodies: PerCP-Cy5.5 anti-CD8a (53-6.7) for 
identification of CD8 T cells, FITC anti-CD4 (RM4-5) for CD4 T cells, APC-Cy7 anti-CD45 
(30-F11) for total leukocytes identification, APC anti-CD69 (H1.2F3), recognizing the early 
activation marker, and PE-Cy7 anti-CD44 (IM7) (1:100; BD Pharmingen) as an homing 
marker. Data were analyzed using FlowJo Software (V 10.0.8). 
 
2.8 Statistical Analysis 
Sample size was pre-estimated on the basis of previously published research and from pilot 
experiments. Data distribution was assessed with D’Agostino Pearson test, and assumption 
of homogeneity of variance was tested using Levene's Test of Equality of Variances. 
Statistical significance was assessed with the appropriate test according to each 
experimental design. In details, multiple group analysis was performed with Two-way ANOVA 
followed by Bonferroni’s post hoc and analysis for repeated measures was applied when 
required by the experimental setting. Data are presented as mean ± SEM. P<0.05 was 
considered significant. Statistical analyses were performed with SPSS 23.0 (IBM Software) 
and graphs were made with GraphPad Software PRISM5. 
 
3. Results 
3.1 DOCA-salt hypertension recruits a sympathetic neural regulation of the spleen 
The consolidated notion that hypertension induced by DOCA-salt challenge associates with 
T cells infiltration in the kidney8, 9, raised the interest in the search for molecular mechanisms 
regulating immune system upon this hypertensive hit. Despite immune mechanisms 
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contributing to renal damage and BP regulation in DOCA-salt hypertension have been 
proposed21, we still ignore how lymphoid organs participate in the etiology of the disease. To 
gain information into this issue, we challenged splenectomized mice with DOCA-salt and 
measured BP. Mice deprived of the splenic immune system were unable to rise BP upon the 
salt-sensitive hypertensive stimulus (Figure 1A and B), conversely to what is typically 
observed in control mice (Figure 1A and B), thus suggesting a relevant role of splenic immune 
cells in DOCA-salt hypertension. We previously found that splenic nerve activity is sensitive 
to this hypertensive hit, as reflected by increased firing activity of the nerve early after DOCA-
salt administration18. Here we found that DOCA-salt induces a precocious increase in the 
expression of Tyrosine Hydroxylase (TH), the rate limiting enzyme of noradrenaline (NA) in 
the marginal zone (MZ) of the spleen, defined by CD169+ metallophilic macrophages (Figure 
1C and D). In order to ascertain the dependence of this sympathetic input on the nervous 
drive passing through the coeliac ganglion, we analyzed TH expression in a further group of 
mice where CGX was performed before DOCA-salt administration. DOCA-salt was unable to 
induce TH expression in mice subjected to CGX (Figure 1C), being the % of TH stained area 
in the spleen significantly reduced compared to sham mice subjected to the same challenge 
(Figure 1 D). This result was further confirmed by the quantitative measurement of NA in the 
spleen, showing that DOCA-salt increased NA content and that CGX was effective in 
hampering its induction (see Supplementary material online, Figure S1A). In order to assess 
the selectivity of this procedure in denervating the spleen without affecting the renal 
innervation, we also measured the NA content of contralateral kidney, which resulted 
unaffected (see Supplementary material online, Figure S1B). To add information on the 
functional relevance of this pathway, we monitored BP response to DOCA salt challenge in 
a further group of CGX mice, as compared to the sham controls, finding that they were 





Figure 1. DOCA-salt challenge requires a neurosplenic drive to induce hypertension. 
(A, B) Tail cuff BP measurements to monitor the response to DOCA-salt, in sham 
and splenectomized mice, as compared to the placebo treated groups. Panels 
represent mean ± SEM values of systolic BP (SBP) (A) and diastolic BP (DBP) (B). 
∗∗∗p<0.001 sham DOCA-salt mice vs all the other groups (n=4 mice for each group). 
(C) Immunostaining of Tyrosine Hydroxylase (TH) (Cy3-conjugated secondary 
antibody, magenta) in the MZ of the spleen, labeled with anti-CD169 (Alexa488-
conjugated secondary antibody, yellow) antibody for metallophilic macrophages, in 
sham and CGX mice, treated with DOCA-salt or placebo. Images represents n=5 
mice for each group; scale bar 200 m. (D) Graph showing the quantitative analysis 
of TH expression as % of stained area. ∗∗p<0.01. (E, F) Tail cuff BP measurements 
to monitor the response to DOCA-salt, in sham and CGX mice. Panels represent 
mean ± SEM values of SBP (E) and DBP (F). ∗∗∗p<0.001 sham DOCA-salt mice vs 




Figure S1. CGX significantly decreased the noradrenaline content in the spleen 
but not in the ipsilateral kidney after DOCA-salt. (A) Noradrenaline release in the 
spleen of Sham and CGX mice upon DOCA-salt or placebo expressed as nmol*10-
3/mg of wet tissue as determined by ELISA. *p<0.05 (n=5 mice for Sham placebo, 
n=6 for Sham DOCA-salt, n=7 for CGX placebo and n=5 for CGX DOCA-salt). (B) 
Noradrenaline release in the ipsilateral kidney from sham and CGX mice upon 
DOCA-salt or placebo, expressed as nmol*10-3/mg of wet tissue as determined by 
ELISA (n=3 mice for Sham placebo, n=4 for Sham DOCA-salt, n=5 for CGX 
placebo and n=4 for CGX DOCA-salt). 
 
3.2 PlGF is critically involved in DOCA-salt-induced hypertension 
Previous studies showed that neural modulation of the spleen can have several effects in 
different pathophysiological contexts13,18,22 and that the pathway activated by PlGF is crucial 
in immune functions involved in hypertensive responses to AngII. Thus, we sought to 
determine whether this pathway could be involved in mediating the response to DOCA-salt. 
Immunofluorescence analysis showed that DOCA-salt administration significantly induced 
PlGF expression in the MZ of the WT spleen, marked by the co-staining with CD169 
metallophilic macrophages (Figure 2A and B) and ERT-R7 fibroblast reticular cells (see 
Supplemental material online, Figure S2A), as compared to the basal levels found in mice 
treated with placebo alone (Figure 2A and B). As expected no signal of staining positive for 
PlGF was found in PlGF KO mice (Figure 2A and B). To determine whether the activation of 
PlGF pathway was directly induced in the spleen or mediated by the increased sympathetic 
splenic drive activated by DOCA-salt, the % of PlGF positive area was also measured in mice 
subjected to CGX prior to starting the hypertensive challenge. As shown by 
immunofluorescence and related quantitative analysis, the sympathetic denervation of the 
spleen hampered PlGF expression upon DOCA-salt (Figure 2A and B). In addition, we 
quantitatively measured PlGF protein levels, released in the spleen after DOCA-salt 
challenge, confirming the finding of a sympathetic-dependent release of PlGF upon DOCA-
salt (Figure 2C). We next questioned whether this pathway had an impact on the hypertensive 
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phenotype. Thus, we subjected PlGF KO mice and their WT controls to the 21 days protocol 
of DOCA-salt administration or placebo and chronically measured BP both by radiotelemetry 
and tail cuff. The results evidenced an indispensable role of PlGF to allow BP increase upon 
DOCA-salt challenge (Figure 2D and E, see Supplemental material online, Figure S2B and 
C). As expected, placebo had no effect on BP of both genotypes (Figure 2D and E, see 
Supplemental material online, Figure S2B and C). 
Data obtained so far, proposed PlGF as a mediator of the neuroimmune drive recruited by 
DOCA-salt in the spleen. To rule out the possibility that this effect could be due to an 
impairment of PlGF KO in the activation of the sympathetic splenic drive, we assessed the 
effects of DOCA-salt on TH expression in the spleen. As shown by immunofluorescence and 
quantitative analysis of TH positive area in the MZ, there was no difference in the levels of 
up-regulation of SNS induced by DOCA-salt in PlGF KO mice as compared to WT controls 
(see Supplemental material online, Figure S3A and B), thus suggesting a local splenic effect 
of PIGF. Taken together these results support the hypothesis that PlGF is the mediator of the 






Figure 2. DOCA-salt activates noradrenergic-mediated release of PlGF in the spleen 
to induce BP increase. (A) Immunostaining of PlGF (Alexa488-conjugated 
secondary antibody, red) in splenic MZ, labeled with anti-CD169 antibody (Cy3-
conjugated secondary antibody, yellow), showing the effect of DOCA-salt on PlGF 
levels in WT mice, with or without CGX, and in PlGF KO mice as negative control. 
Images are representative of n=4 mice for each group; scale bar 200 m. (B) Graph 
showing the quantitative analysis of PlGF expression as % of stained area. *p<0.05 
and ***p<0.001. (C) Quantitative analysis of PlGF protein levels in the spleen of mice 
treated with DOCA-salt with intact (sham) or denervated (CGX) sympathetic drive. 
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Levels of PlGF protein in PlGF KO mice are shown as controls. *p<0.05, **p<0.01 
and ***p<0.001 (WT: n=7 for placebo and n=6 for DOCA-salt; PlGF KO: n=4 for 
placebo and n=6 for DOCA-salt; CGX: n=7 for placebo and DOCA-salt). (D, E) Tail 
cuff BP measurements to monitor the response of PlGF KO to DOCA-salt or placebo, 
as compared to WT mice. Panels represent mean ± SEM values of SBP (D) and 





Figure S2. DOCA-salt induces PlGF through noradrenergic fibers in the stromal 
tissue of the spleen. (A) Immunostaining of PlGF (Alexa488-conjugated antibody, 
red) in the stromal zone of the spleen, labeled with anti-ER-TR7 antibody (Cy3-
conjugated antibody, white), isolated from WT mice with an intact (Sham) or 
denervated (CGX) splenic sympathetic drive and from PlGF KO mice as negative 
controls. All groups were treated with DOCA-salt or placebo. Images represent n=4 
mice per group; scale bar 200 m. (B, C) Radiotelemetric monitoring of arterial blood 
pressure upon DOCA-salt in PlGF KO and WT mice measured for 21-days. Panels 
represent mean ± SEM values of systolic blood pressure (SBP) (B) and diastolic 
blood pressure (DBP) (C). ∗∗∗p<0.001 after DOCA-salt in WT vs PlGF KO mice (n=4 






Figure S3. DOCA-salt increases the amount of Tyrosine Hydroxylase (TH) in both 
PlGF KO and WT mice. (A) Double staining for Tyrosine Hydroxylase (TH) (Cy3-
conjugated secondary antibody, magenta) and anti-CD169 (Alexa488-conjugated 
secondary antibody, yellow) antibody for metallophilic macrophages of the splenic 
marginal zone (MZ), in PlGF KO and WTmice treated with DOCA-salt or placebo. 
Scale bar 200 m. (B) The relative quantitative analysis is shown in panel B (n=5 for 
each group). 
 
3.3 DOCA-salt-induced activation of co-stimulation process and deployment of T cells 
for consequent infiltration in target organs depends on PlGF 
In order to investigate to which extent the activation of splenic PlGF mediated by DOCA-salt 
induced sympathetic splenic overdrive, could affect the immune response involved in 
damage of target organs of hypertension, we assessed the amount of T cell deploying from 
the spleen. We evaluated by immunofluorescence analysis the area of CD3+ T cells in the 
white pulp of the spleen, revealed by co-staining with B220 labeled B cells. DOCA-salt 
induced a significant egression of T cells in WT mice, whereas the spleens of PlGF KO mice 
remained unaffected, maintaining an equal amount of CD3+ T cells as compared to placebo 
treated mice (Figure 3A and B). On this notice, it has been previously shown that DOCA-salt 
activates the process of T cells co-stimulation mediated by CD86, which is one of the main 
critical step in the full activation of T cells and prodromal for the later deployment from 
lymphoid organs8, 13, 18, 23. Thus, we tested whether the neuroimmune modulation exerted by 
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DOCA-salt in the spleen and mediated by PlGF was relevant for the activation of 
costimulation. To this aim, we analyzed the amount of CD86 positive staining, a typical 
pattern of activation expressed by antigen presenting cells (APC) in the MZ and known to be 
regulated by DOCA8. Here we show that PlGF is indispensable to allow DOCA-salt induced 
co-stimulation on APC, being CD86 expression hampered in PlGF KO mice (Figure 3C and 
D) infiltration of activated immune cells in target organs, a crucial event contributing to BP 
increase and end-organ damage9, 13. 
Kidneys isolated from DOCA-salt treated mice were analyzed for determination of activated 
T cells content by flow cytometry. As shown by representative plots and quantitative analysis, 
WT mice subjected to DOCA-salt accumulated a significant amount of CD8 and CD4 T cells 
positive for markers of activation (CD69) and homing (CD44), as compared to placebo treated 
mice (Figure 4A-F). Conversely, kidneys isolated from PlGF KO mice were spared from 
infiltrating activated CD8 and CD4 T cells, showing no significant difference when compared 
with placebo treated mice (Figure 4A-F). We further added evidence to this result by looking 
at immune cells infiltrating kidneys with immunohistochemistry (see Supplemental material 
online, Figure S4A-D). Indeed, PlGF KO mice were protected from the significant increase of 
CD4+ T and CD8+ T cells observed in the renal tubules and glomeruli of WT mice challenged 
with DOCA-salt, as compared to mice receiving placebo alone (see Supplemental material 





Figure 3. DOCA-salt induces T cells egression from the spleen by activating co-
stimulation through PlGF. (A) Immunostaining of CD3+ T cells (Cy3-conjugated 
secondary antibody, magenta) in the white pulp area of the spleen and B220 
(Alexa488-conjugated secondary antibody, green) for B cells labeling. (B) 
Quantitative analysis of the area of the spleen positive for CD3. Images represents 
n=5 mice for each group; scale bar 200 m. **p<0.01 and ***p<0.001. (C) Staining 
of CD86 (Alexa488-conjugated secondary antibody, cyan) in the marginal zone of 
the spleen labeled with anti-CD169 antibody (Cy3-conjugated secondary antibody, 
yellow), showing cells positive for the co-stimulation molecule. Images represent n=5 
mice for group; scale bar 50 m. (D) Quantitative analysis of CD86 expressed as % 






Figure 4. PlGF KO mice are protected from DOCA-salt induced infiltration of 
activated T cells in kidneys. (A-D) Plots of flow cytometry analysis showing CD4+ 
and CD8+ T cells infiltrating kidneys of PlGF KO and WT mice, treated with DOCA-
salt or placebo. (E, F) Graphs showing the quantitative analysis of CD4 and CD8 T 
cells, positive for the homing marker CD44 and for the early activation marker CD69, 
in PlGF KO and WT mice, treated with DOCA-salt or placebo. ∗p<0.05, **p<0.01 and 
∗∗∗p<0.001 (n=10 mice for PlGF WT placebo; n=9 mice for PlGF KO placebo; n=14 






Figure S4. PlGF deficiency reduces the chronic inflammation of kidneys induced by 
DOCA-salt. (A, B) Immunostaining and quantitative analysis of CD4+ and CD8+ T 
cells in kidneys of PlGF KO and WT mice after 21 days of DOCA-salt or placebo 




3.4 PlGF KO mice are protected from DOCA-salt induced end-organ damage 
To determine whether the protection from renal infiltration of activated immune cells, 
observed in PlGF KO upon DOCA-salt challenge resulted in protection from end-organ 
damage, we assessed renal fibrosis and glomerular injury. We found that upon DOCA-salt 
administration WT mice showed a significant amount of renal fibrosis, evidenced by staining 
kidneys with Picrosirius Red and Masson’s Trichrome (Figure 5A-C). Instead PlGF KO mice 
were protected from renal fibrosis (Figure 5A-C), thus paralleling the observation that PlGF 
KO kidneys were spared from infiltrating activated T cells. The apposition of fibrotic tissue in 
WT mice treated with DOCA-salt was particularly evident in both glomeruli and tubules, thus 
suggesting that infiltrating T cells negatively affect tissue homeostasis, determining in the 
long term structural alterations that could deteriorate renal function, further contributing to the 
hypertensive phenotype. Accordingly, we also observed that chronic DOCA-salt challenge 
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provoked an enlargement of renal corpuscle size and an increase of glomerular dimensions 
with an irregular area, as represented by PAS staining, which was otherwise absent in PlGF 
KO mice (Figure 5D and E; see Supplemental material online, Figure S5A). The enlargement 
of Bowman’s capsule size displayed by WT mice subjected to DOCA-salt was similarly 
reduced in PlGF KO mice (see Supplemental material online, Figure S5B), thus further 
supporting that the inhibition of immune system activation and recruitment to target organs 
obtained in the absence of PlGF was effective in preventing not only BP increase but also 
end-organ damage. Lastly, to provide functional data related to the above described renal 
injury, we assessed key parameters of renal function in PlGF KO and WT mice placed in 
metabolic cages at the end of DOCA-salt or placebo administration. A marked increase in 
urine output was observed after 21 days of DOCA-salt (Figure 6A), with a consequent 
reduction of urinary osmolality (Figure 6B). Despite the increase in urine output was 
significantly blunted in PlGF KO mice (Figure 6A), the urinary osmolality was comparable, as 
it was the plasma osmolality, moderately increased in both WT and PlGF KO mice (Figure 
6C), thus suggesting that the stimulus induced by DOCA-salt determined an equal fluid 
balance in the two groups. When we measured renal function, the creatinine clearance was 
significantly reduced in WT mice but preserved in PlGF KO mice (Figure 6D). Similarly, PlGF 
KO mice were preserved from the DOCA-salt induced renal damage observed in WT mice, 
in terms of protein excretion, measured as total proteins to creatinine ratio. In fact, the marked 
increase observed in WT mice after 21 days of DOCA-salt was significantly hampered in 






Figure 6. Renal end-organ damage induced by DOCA-salt is significantly hampered 
by PlGF deficiency. (A-C) Evaluation of fluid balance in PlGF KO and WT mice 
treated with DOCA-salt as shown by urine output (A), urine (B) and plasma (C) 
osmolality, measured in mice placed in metabolic cages. (D) Analysis of renal 
function expressed as creatinine clearance (Cr Cl) in the 24 hours in PlGF KO and 
WT mice after DOCA-salt or placebo treatment. (E) Protein excretion is expressed 
as the ratio between total urinary proteins and urinary creatinine in PlGF KO and WT 
mice, treated with DOCA-salt or placebo. *p<0.05, **p<0.01 and ***p<0.001 (n=5 
mice for PlGF WT placebo, n=6 for PlGF WT DOCA-salt and PlGF KO placebo, n= 







Figure S5. PlGF KO mice are protected from the renal structural damage caused by 
chronic DOCA-salt. (A, B) Quantitative analysis of PAS staining showing the 
estimated measure of the Bowman’s capsule size (B), and glomerular dimensions 
(A), in PlGF KO and WT mice, treated with DOCA-salt or placebo. ∗<0.05, ∗∗p<0.01 





The main findings of this study put in evidence that the activation of PlGF in the spleen is 
necessary to couple the brain-mediated effects of DOCA-salt challenge to the activation of 
immune cells directed toward kidneys, where they contribute to BP increase and organ 
damage. Summarizing our results (Figure 7), we here show that: 1) DOCA-salt challenge 
requires splenic immunity to drive hypertension and 2) exploits the splenic sympathetic 
innervation to activate T cells through PlGF release in the MZ; 3) PlGF KO mice are protected 
from hypertension and target organ damage.  
Overall these data suggest that the brain-to-spleen neuroimmune circuit is a common 
pathway activated by different hypertensive hits, like AngII and DOCA-salt, to prime an 
immune response necessary to establish the hypertensive disease. Previous works 
highlighted how DOCA-salt challenge, mostly known to reproduce a condition of peripherally 
depressed RAS activity4, frequently found also in hypertensive patients24, strongly activates 
signaling pathways in circumventricular organs, similarly to what observed upon AngII1, 6, 7, 14, 
15, 24, 25. It is notable that a denervation of splanchnic sympathetic innervation of the spleen, 
obtained through left CGX here proved to be effective in blocking BP increase in mice 
administered with DOCA-salt. Previous reports also showed that splanchnic innervation is 
crucial for AngII and DOCA-salt responses in rats26, 27. Additionally, a previous work by the 
group of Fink reported that the same model of DOCA-salt hypertension was not characterized 
by a generalized sympathoexcitation28, adding evidence to the notion that AngII and DOCA-
salt hypertensive hits act in a completely different way in the periphery. However, this is not 
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surprising as one of the main feature of the SNS is its highly heterogeneous regionality. Data 
presented in this work also evidence that the pathway mediating a neural modulation of 
immunity upon DOCA-salt hypertension, is not involved in the sensing of the stimulus, 
showing PlGF KO mice a similar pattern of fluid intake regulation. Whereas it becomes clear 
that the neuroimmune pathway mediated by splenic PlGF is downstream to sensing stations 
of DOCA-salt and primes immune cells lastly responsible for renal effects relevant for BP 
regulation and end-organ damage.  
Overall, previous and present findings support the concept that a specific pattern of 
splanchnic SNS activity, required for the activation of immune system in the spleen, is 
commonly recruited by different hypertensive challenges, acting through distinct peripheral 
mechanisms of action. 
Hypertension is indeed a complex disorder that may arouse because of a wide variety of hits 
to BP homeostasis29, 30. Some of the mechanisms involved in regulation of BP levels are very 
different and various experimental models of hypertension have been developed in the 
attempt to recapitulate this complexity. DOCA-salt and chronic AngII are among the most 
used approaches to model different conditions observed in the human pathology. Despite the 
huge work that has been done to understand the different pathophysiological mechanisms 
underlying hypertension in these two conditions, it emerges now that their capability to 
commonly recruit the brain-to-spleen circuit, a primer of adaptive immunity, previously shown 
to crucially participate to the hypertensive disease characterized in both models. These 
findings further add a piece of knowledge in the understanding of how neuroimmune reflexes 
participate to the modulation of cell trafficking and lymphoid architecture in different 
pathophysiological contexts31. Notably, ablation of this neurosplenic axis has no effect in 
basal conditions, whereas it effectively protects from hypertension and its related target organ 
damage. The fact that the neurosplenic axis is dispensable in physiological conditions but 
essential in hypertension sounds particularly important in terms of translational perspectives. 
A last opportunity from the clinical point of view is suggested by the availability of antibodies 
targeting PlGF already under investigation in advanced therapies for cancer and macular 
degeneration32-34. The insights here proposed, reporting the activation of a common 
neuroimmune mechanism underlying the hypertensive disease from different causes, 
strongly encourage the possibility to exploit a therapeutic strategy blocking this pathway, as 
a novel clinical opportunity for patients resistant to all ongoing available medications. On a 
different notice, our results also warrant another reflection relevant for the clinical implications 
emerging from the proof of concept that targeting PlGF mediated pathway would protect from 
hypertension. There is a consistent and increasing amount of reports in the literature that 
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associates the use of anti-angiogenic therapies, mainly based on inhibitors of the VEGF 
(growth factor belonging to the same family of PlGF), with increased cardiovascular risk and, 
especially, induction of hypertension35. In principle, one would have expected that PlGF 
inhibition could have similar effects. Instead our previous and present data demonstrate that 
it is not the case, being PlGF inhibition associated with a protection from BP increase and 
target organ damage in experimental models of hypertension. On this basis, data acquired 
so far would suggest that the inhibition of PlGF in cancer would have a dual positive role: on 
the one hand, it would protect from tumor growth32-34, 36, 37 and at same time hamper 




Figure 7. PlGF mediates the neural modulation exerted by the splenic sympathetic 
drive activated by DOCA-salt to induce hypertension. Pathophysiological circuit of 
neural modulation of immune system in DOCA-salt hypertension. The schematic 
representation recapitulates the three main steps involved in sensing and 
transduction of DOCA-salt neuro-immune effects. 1) DOCA-salt acts on the brain to 
activate the splenic sympathetic drive passing through the coeliac ganglion and 
reaching the spleen where 2) noradrenaline release mediates PlGF production in the 
MZ. In turn, PlGF production is necessary to allow T cells co-stimulation by 
increasing the expression of CD86 co-stimulation molecule, a permissive step for 
deployment of T cells from lymphoid organs. 3) Activated T cells reach kidneys 
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Hypertension shares an intriguing feature with the innovative researches in immunology on 
one hand and the classical mechanisms of blood pressure regulation through nervous circuits 
mediated by the sympathetic nervous system on the other hand. 
In this dissertation, it is highlighted the interaction between the immune system in 
physiological dysfunctions contributing to end-organ damage, the typical hallmark of the 
disease, and the sympathetic nervous system in the modulation of immune cells in the spleen 
in two different murine model of hypertension.  
As previously discussed, the increase of arterial blood pressure in experimental model 
induced by different stimuli, as AngII or DOCA-salt, affects the RAS in the brain. In the first 
work, we show that the cholinergic-sympathetic drive in hypertension is realized through a 
vagus-splenic nerve connection from the brain to the spleen and it is able to activate the T 
cells in the spleen, then recruited in target organs of hypertension as kidney and vasculature, 
where they contribute to the development of hypertension. Both the hypertensive stimuli, 
AngII and DOCA-salt, increase the discharge of the splenic nerve that is dependent on an 
intact vagus nerve efferent. The coeliac branch of the vagus nerve terminates in the coeliac 
ganglion where the catecholaminergic fibers of the splenic nerve originate. This interaction is 
mediated by the 7nAChR expressed in the coeliac ganglion. Indeed, 7nAChR KO mice 
are protected from blood pressure increase upon chronic AngII and from egression of 
immune cells towards aorta and kidney. At the end, we propose an important translational 
implication with a completely innovative approach on the splenic nerve by the thermoablation, 
a selective procedure of denervation, which is protective against the raising of blood pressure 
levels induced by chronic AngII. 
The novelty of this work is the concept that the autonomic nervous system is capable to 
determine long-term effects on the cardiovascular system in pathological states through the 
regulation of the immune system. The spleen is a secondary lymphoid organ directly and 
densely innervated by the sympathetic nervous system and as suggested by some milestone 
papers in hypertension, the AngII is responsible of a variety of actions that contribute to the 
development of hypertension, as well as the DOCA-salt treatment.  
In the past researches conducted in my lab, it was found that the PlGF was a mediator of the 
effect on arterial blood pressure caused by chronic AngII. PlGF drives the interaction between 
the sympathetic nervous system and the immune system in the spleen in response to AngII, 
playing a central role in the regulation of blood pressure raising.  
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In the second part of this work, we hypothesize that the PlGF, coupling the nervous and the 
immune system in the spleen, could mediate T cells activation induced by DOCA-salt in mice 
and their infiltration into target organs of hypertension. In this study, we demonstrate that its 
expression in the spleen, where it drives immune responses, depends on the integrity of 
splenic sympathetic innervation acting as an interface between the sympathetic and immune 
system. The main result of this work is that chronic DOCA-salt enhances splenic sympathetic 
nerve fibers establishing a communication with immune cells in the spleen by PlGF. Upon 
this hypertensive stimulus, KO mice display a reduction of blood pressure levels and 
furthermore coeliac ganglionectomy mice exhibit decreased levels of PlGF in the marginal 
zone of the spleen. The coeliac ganglion appears as a central site whence the sympathetic 
innervation branched until the spleen and surprisingly, the removal of this central ganglion is 
useful to reduce significantly the PlGF levels in the spleen of this hypertensive murine model. 
We demonstrate that this hypertensive challenge shares with AngII a common central 
mechanism of action activating the brain RAS. 
Hence, the lack of splenic PlGF determinate a protection from costimulation and egression 
of T cells from the splenic reservoir, considering PlGF as an important mediator in 
hypertension induced by DOCA-salt.  
Given its roles in angiogenesis, PlGF has been studied as a molecular target for cancer 
treatment and interestingly, one of the main effect of anti-PlGF therapies concerns 
cardiovascular diseases. In perspective, the discovery of its molecular pathway in 
hypertension could have more implications: certainly, could lead to further knowledge on 
molecular mechanisms causing the onset of the disease in order to assess a holistic therapy 
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